IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL  (INCL . AMENDMENT #3) : FINAL  VERSION 4.0: 13 NOVEMBER  2023  PAGE 1
 
 Protocol Title:  
Rollover Study; Multicentre,  Phase III, Open -label Study to Further Evaluate the Safety and 
Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with 
Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO -1A-301 or 
PVO -1A-202/PVO -1A-204 an d May Benefit from Palovarotene Therapy.  
 
Protocol Number: CLIN -[ZIP_CODE] -452 
Compound:  Palovarotene  (IPN [ZIP_CODE] ) 
 
Study Name: [CONTACT_976][INVESTIGATOR_775920]:  
A Rollover Study to Further Evaluate the Safety  and Efficacy of Palovarotene Capsules in Male 
and Female Participants Aged ≥14 Years with Fibrodysplasia Ossificans Progressiva (FOP)  
Who Have Completed the Relevant Parent Studies.  
 
Study Phase: III  
 
Sponsor Name:   [CONTACT_776032]:  65, quai Georges Gorse  
[ADDRESS_1065766]  
Paris, [LOCATION_009]  
 
Regulatory Authority Identifier Number(s) : 
IND number: [ADDRESS_1065767] number:  2021 -002244 -70 
 
Date : 13 November  2023  
Version number : 4.[ADDRESS_1065768] understand that it is strictly confidential.  
Information contained herein cannot be disclosed, submitted for publication or used for any 
purpose other than that contemplated herein without the sponsor’s prior written 
authorisation.

P P D 
P P D 
IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065769] read and agree to Protocol CLIN-[ZIP_CODE] -452 entitled ‘Rollover Study; Multicentre, Phase 
III, Open -label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in 
Male and Female Participants Aged ≥14 Years with Fibrodysplasia Ossificans Progressiva 
(FOP) Who Have Co mpleted Study PVO -1A-301 or PVO -1A-202/PVO -1A-204 and May 
Benefit from Palovarotene Therapy ’. I am aware of my responsibilities as an investigator under 
the guidelines of Good Clinical Practice (GCP), local regulations (as applicable) and the study 
protoco l. I agree to conduct the study according to these guidelines and to appropriately direct 
and assist the staff under my control, who will be involved in the study.  
 
NAME:   
[CONTACT_288308]:  [PRINCIPAL]  SIGNATURE:  
 [CONTACT_325598]:  
 
OFFICE:   
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065770] of Protocol Amendments  
Amendment  Release date  Amendment form  
1 01 October  2021  Section 10.7 
2 28 April 2022  Section  10.8 
3 13 November  2023  Section 10.9 
 
Amendment #3 (13 November  2023 ) 
This amendment is considered non-substantial . 
Overall Rationale for the Amendment  
This amendment aimed to:  
• Update safety and efficacy background information ; 
• Provide clarification on remote follow -up and EOS/EW visits ; 
• Provide clarification on extra bone growth assessment ; 
• Remove the temporary measures related to the COVID -19 pandemic ; 
• Add the blister packaging  and the packaging format for US patients (15 capsules 
packaged in bottle (5 mg))  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065771] OF ABBREVIATION S ................................ ................................ ................................  10 
1 PROTOCOL SUMMARY  ................................ ................................ ...........................  13 
1.1 Synopsis  ................................ ................................ ................................ ..........................  13 
1.2 Schema  ................................ ................................ ................................ ...........................  20 
1.3 Schedule of Activities  ................................ ................................ ................................ .... 20 
2 INTRODUCTION  ................................ ................................ ................................ ........  23 
2.1 Study Rationale  ................................ ................................ ................................ .............  23 
2.2 Background  ................................ ................................ ................................ ...................  23 
2.2.1  Disease Background  ................................ ................................ ...................  23 
2.2.2 Treatment Background  ................................ ................................ ...............  24 
2.2.3  Safety Profile of Palovarotene  ................................ ................................ .... 25 
2.2.4  Efficacy of Palovarotene  ................................ ................................ .............  26 
[IP_ADDRESS]  Phase II Studies  ................................ ................................ ............................  26 
[IP_ADDRESS]  Phase III Study  ................................ ................................ .............................  26 
2.3 Benefit/Risk Assessment  ................................ ................................ ...............................  27 
2.3.1  Risk Assessment  ................................ ................................ ..........................  27 
2.3.2  Benefit Assessment  ................................ ................................ ......................  29 
2.3.3  Overall Benefit: Risk Conclusion  ................................ ...............................  29 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .............  30 
4 STUDY DESIGN  ................................ ................................ ................................ ...........  32 
4.1 Overall Design  ................................ ................................ ................................ ...............  32 
4.2 Scientific Rationale for Study Design  ................................ ................................ ..........  33 
4.2.1  Participant Input into Design  ................................ ................................ ..... 34 
4.3 Justification for Dose  ................................ ................................ ................................ .... 34 
4.4 End of Study Definition  ................................ ................................ ................................  35 
5 STUDY POPULATION  ................................ ................................ ...............................  37 
5.1 Inclusion Criteria  ................................ ................................ ................................ ..........  37 
5.2 Exclusion Criteria  ................................ ................................ ................................ .........  38 
5.3 Lifestyle Considerations  ................................ ................................ ...............................  38 
5.4 Screen Failures  ................................ ................................ ................................ ..............  38 
6 STUDY INTERVENTION A ND CONCOMITANT THERA PY ............................  40 
6.1 Study Intervention Administered  ................................ ................................ ................  40 
6.2 Preparation, Handling, Storage and Accountability  ................................ .................  42 
6.3 Measures to Minimise Bias: Randomisation and Blinding  ................................ ....... 43 
6.3.1  Randomisation  ................................ ................................ ............................  43 
6.3.2  Maintenance of Blinding  ................................ ................................ ............  43 
6.4 Study Intervention Administration/Accountability  ................................ ...................  43 
6.5 Dose Modification  ................................ ................................ ................................ .........  43 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 6
 
 6.6 Continued Access to Study Intervention after the End of the Study  .......................  44 
6.7 Treatment of Overdose  ................................ ................................ ................................ . 44 
6.8 Prior and Concomitant Therapy  ................................ ................................ .................  44 
6.8.1  Preventive Medication  ................................ ................................ .................  45 
6.8.2  Rescue Medicine  ................................ ................................ .........................  45 
7 DISC ONTINUATION OF STUDY  INTERVENTION AND PA RTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ... 47 
7.1 Discontinuation of Study Intervention  ................................ ................................ ........  47 
7.1.1  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ .............................  47 
7.1.2  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................  47 
7.1.3  Treatment Interruption  ................................ ................................ ...............  47 
7.1.4  Rechallenge  ................................ ................................ ................................ . 47 
7.2 Partic ipant Discontinuation/Withdrawal from the Study  ................................ ........  [ADDRESS_1065772] to Follow -up ................................ ................................ ................................ ..........  48 
8 STUDY ASSESSMENTS AN D PROCEDURES  ................................ .......................  49 
8.1 Efficacy Assessments  ................................ ................................ ................................ .... 49 
8.1.1 FOP -PFQ  ................................ ................................ ................................ .... 49 
8.1.2  PROMIS Global Health Scale  ................................ ................................ .... 49 
8.1.3  CAJIS  ................................ ................................ ................................ ..........  50 
8.1.4  FOP Assistive Devices Assessment  ................................ .............................  50 
8.1.5  Healthcare Utilisation  ................................ ................................ .................  51 
8.1.6  Lung Function Assessments  ................................ ................................ ....... 51 
8.1.7  Flare -up Assessment  ................................ ................................ ...................  51 
8.1.8  Extra Bone Growth Assessment (without associated flare -up) .................  52 
8.1.9  Qualitative Participant In terviews  ................................ ..............................  52 
8.2 Safety Assessments  ................................ ................................ ................................ ........  52 
8.2.1  Spi[INVESTIGATOR_775921]  ................................ ................................ ...........  52 
8.2.2  C-SSRS and Suicidal Ideation and Behaviour Risk Monitoring  ..............  53 
8.2.3  Biochemistry and Triglycerides  ................................ ................................ .. 53 
8.2.4  Linear Height and Body Weight  ................................ ................................ . 53 
8.2.5  Vital Signs  ................................ ................................ ................................ ... 54 
8.2.6  Preg nancy Testing  ................................ ................................ .......................  54 
8.3 AEs and SAEs and Other Safety Reporting  ................................ ...............................  54 
8.3.1  Time Period and Frequency for Collecting AE and SAE Information  .... 55 
8.3.2  Method of Detecting AEs and SAEs  ................................ ...........................  55 
8.3.3  Follow -Up of AEs and SAEs  ................................ ................................ ...... 55 
8.3.4  Regulatory Reporting Requirements for SAEs  ................................ ..........  55 
8.3.5  Pregnancy  ................................ ................................ ................................ .... 56 
8.3.6  Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs  ................................ ................................ .........  [ADDRESS_1065773]  ................................ .............................  56 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 7
 
 8.3.8  Reporting of Study  Intervention Errors Including Misuse/Abuse  ............  56 
8.4 Pharmacokinetics  ................................ ................................ ................................ ..........  57 
8.5 Genetics  ................................ ................................ ................................ ..........................  57 
8.6 Biomarkers  ................................ ................................ ................................ ....................  57 
8.7 Immunogeni city Assessments  ................................ ................................ ......................  57 
8.8 Medical Resource Utilisation and Health Economics  ................................ ................  57 
8.9 Demographic and Baseline Characteristics  ................................ ................................  57 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  58 
9.1 Statistical Hypotheses  ................................ ................................ ................................ ... 58 
9.1.1  Multiplicity Adjustment  ................................ ................................ ...............  58 
9.2 Sample Size Determination  ................................ ................................ ..........................  58 
9.3 Analysis Sets  ................................ ................................ ................................ ..................  58 
9.4 Statistical Analyses  ................................ ................................ ................................ ....... 58 
9.4.1  General Considerations  ................................ ................................ ..............  58 
9.4.2  Analysis of Primary Endpoint  ................................ ................................ .... 59 
9.4.3  Analysis of Secondary Endpoints  ................................ ...............................  59 
[IP_ADDRESS]  FOP -PFQ  ................................ ................................ ................................ ..... 59 
[IP_ADDRESS]  PROMIS Global Health Scale  ................................ ................................ ..... 60 
[IP_ADDRESS]  CAJIS  ................................ ................................ ................................ ...........  61 
[IP_ADDRESS]  FOP Assistive Devices  ................................ ................................ .................  61 
[IP_ADDRESS]  Healthcare Utilization  ................................ ................................ .................  61 
[IP_ADDRESS]  Lung Function Parameters  ................................ ................................ ..........  61 
[IP_ADDRESS]  Flare -ups ................................ ................................ ................................ ...... 61 
[IP_ADDRESS]  Extra Bone Growth  ................................ ................................ ......................  61 
[IP_ADDRESS]  Qualitative Participant Interviews  ................................ ...............................  62 
9.4.4  Other Analyses  ................................ ................................ ............................  62 
[IP_ADDRESS]  Demographic and Baseline Characteristics  ................................ ................  62 
[IP_ADDRESS]  Prior and Concomitant Medication  ................................ .............................  62 
[IP_ADDRESS]  Concomitant Procedures  ................................ ................................ .............  62 
[IP_ADDRESS]  Spi[INVESTIGATOR_775921]  ................................ ................................ ............  62 
[IP_ADDRESS]  Linear Height and Body Weight  ................................ ................................ .. 62 
[IP_ADDRESS]  Vital Signs  ................................ ................................ ................................ .... 63 
[IP_ADDRESS]  Participant Disposition and Withdrawals  ................................ ...................  63 
9.4.5  Subgroups Analyses  ................................ ................................ ....................  63 
9.5 Interim Analyses  ................................ ................................ ................................ ...........  63 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ .... 64 
10.1  Appendix 1: Regulatory, Ethical  and Study Oversight Considerations  ..................  64 
10.1.1  Regulatory and Ethical Considerations  ................................ .....................  64 
10.1.2  Financial Disclosure  ................................ ................................ ...................  64 
10.1.3  Informe d Consent and Assent Process  ................................ .......................  64 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 8
 
 10.1.4  Data Protection  ................................ ................................ ...........................  65 
10.1.5  Committees Structure  ................................ ................................ ..................  66 
[IP_ADDRESS]  Independent Data Monitoring Committee  ................................ ...................  66 
10.1.6  Dissemination of Clinical Study Data  ................................ ........................  66 
10.1.7  Data Quality Assurance  ................................ ................................ ..............  66 
10.1.8  Source Documents  ................................ ................................ ......................  67 
10.1.9 Study and Site Start and Closure  ................................ ................................  68 
10.1.10  Publication Policy  ................................ ................................ .......................  68 
10.2  Appendix 2: Contraceptive Guidance and Collection of Pregnancy Information  .. 69 
10.2.1  Definitions  ................................ ................................ ................................ ... 69 
10.2.2  Contraception Guidance  ................................ ................................ .............  70 
10.2.3  Collection of Pregnancy Information  ................................ ........................  71 
10.3  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -Up and Reporting  ................................ ................................ ........  72 
10.3.1  Definition of AE  ................................ ................................ ..........................  72 
10.3.2  Definition of S AE ................................ ................................ ........................  73 
10.3.3  Recording and Follow -up of AE and/or SAE  ................................ ............  74 
10.3.4  Reporting of SAEs  ................................ ................................ .......................  75 
10.4  Appendix 4: Clinical Laboratory Tests  ................................ ................................ ...... 76 
10.5  Appendix 5: CYP450 3A4 Inducers or Inhibitors - Exclusionary Medications  ...... 77 
10.6  Appendix 6: Country -Specific Requirements  ................................ ............................  78 
10.6.1  Sweden  ................................ ................................ ................................ .........  78 
10.6.2  Argentina  ................................ ................................ ................................ ..... 78 
10.7  Appendix 7: Protocol Amendment Form No. 1  ................................ .........................  79 
10.8  Appendix 8: Protocol Amendment Form No.  2 ................................ .......................  103 
10.9  Appendix 9: Protocol Amendment Form No.  [ADDRESS_1065774] OF TABLES  
Table  1 Schedule of Activities  ................................ ................................ ..........................  21 
Table  2 Summary of Potential Risks of Study Participation and Mitigation Strategy
 ................................ ................................ ................................ ...............................  27 
Table  3 Objectives and Endpoints  ................................ ................................ ...................  30 
Table  4 Study Intervention Administered  ................................ ................................ ...... 41 
Table  5 Dose Reduction of Palovarotene  ................................ ................................ ........  44 
Table  6 Rescaled Global Physical and Mental Health Scores for the Adult Version 
of the PROMIS Global Health Scale  ................................ ................................ . 60 
Table  7 PROMIS Global Health Scale T -Score Conversions for Global Physical and 
Mental Health Scores  ................................ ................................ ..........................  61 
Table  8 Protocol -Required Safety Laboratory Tests  ................................ .....................  76 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065775] OF FIGURES  
Figure  1 Study Schema  ................................ ................................ ................................ ....... 20 
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065776]  European Clinical Trials Database  
EW Early Withdrawal  
FAS  Full Analysis Set  
FDA  Food and Drug Administration  
FEV 1 Forced Expi[INVESTIGATOR_775922]12  12-kDa FK506 -binding Protein  
FOCBP  Female of Childbearing Potential  
FOP  Fibrodysplasia Ossificans Progressiva  
FOP -PFQ  FOP Physical Function Questionnaire  
FSH  Follicle -stimulating Hormone  
FVC  Forced Vital Capacity  
GCP  Good Clinical Practice  
HEENT  Head, Eyes, Ears, Nose and Throat  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 11  
 
 ABBREVIATION  Wording Definition   
HED  Human Equivalent Dose  
HO Heterotopic Ossification  
HRT  Hormonal Replacement Therapy  
IB Investigator’s Brochure  
ICC International Clinical Council  
ICF Informed Consent Form  
ICH  International Council for Harmonisation  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IFOPA  International Fibrodysplasia Ossificans Progressiva Association  
IND Investigational New Drug  
IRB Institutional Review Board 
IWRS  Interactive Web Response System  
LPLV  Last Participant  Last Visit  
MedDRA  Medical Dictionary for Regulatory Activities  
N Number of available observations  
n Number of nonmissing observations  
NHS  Natural History Study  
OMIM  Online Mendelian Inheritance in Man  
PI [INVESTIGATOR_775923]γ  Retinoic Acid Receptor  Gamma  
SAE  Serious Adverse Event 
SAP  Statistical Analysis Plan 
SAS® Statistical Analysis System  
SD Standard Deviation  
SI Unit  International System of Units  
SoA Schedule of Activities  
SOC  System Organ Class  
SP Service Provider  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065777]  Upper Limit of Normal  
US [LOCATION_002]  
WHODD  World Health Organization Drug Dictionary  
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 13  
 
 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol Title:   
Rollover Study; Multicentre, Phase III, Open -label Study to Further Evaluate the Safety and 
Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with 
Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO -1A-301 or 
PVO -1A-202/PVO -1A-204 and May Benefit from Palovarotene Therapy.  
 
Short Title:   
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male 
and Female Participants Aged ≥14 Years with Fibrodysplasia Ossificans Progressiva (FOP) 
Who Have Completed the Relevant Parent Studies . 
Rationale : 
The aim of Study CLIN -[ADDRESS_1065778] completed one of the parent studies (Study PVO -1A-301 
or PVO -1A-202 (Part s C and D correspond to Study PVO -1A-204 in Franc e)) and , in the 
investigator’s judgement,  may benefit from palovarotene therapy until palovarotene is 
reimbursed  in the country where the study is being conducted, or another access programme 
becomes available, or until the study end date of November [ADDRESS_1065779]. 
Objectives and Endpoints : 
Objectives  Endpoints  
Primary   
• To further evaluate the safety of palovarotene 
in adult and paediatric participants with FOP.  • Incidence and description of all 
treatment -emergent adverse events ( TEAEs) 
whether or not they are considered as related 
to the study intervention;  
• Incidence and description of all serious and 
nonserious treatment -related TEAEs;  
• Incidence and description of all serious 
TEAEs, whether or not they are considered as 
related t o the study intervention;  
• Incidence and description of all nonserious 
TEAEs whether or not they are considered as 
related to the study intervention.  
Secondary   
• To describe range of motion, as assessed by 
[CONTACT_775966] (CAJIS) for FOP, at the Inclusion Visit  
and over time under palovarotene treatment;  • Raw values and change from the Inclusion 
Visit  in CAJIS total score at each Follow-up 
Visit; 
• To describe the use of assistive devices and 
adaptations for daily living by [CONTACT_775967], at the Inclusion Visit and over 
time under palovarotene treatment;  • Raw values and shift from the Inclusion Visit 
in the use of assistive devices an d adaptations 
for daily living at each Follow -up Visit;  
• To describe physical function, using the adult 
form of the FOP Physical Function 
Questionnaire (FOP -PFQ), at the Inclusion • Raw values and change from  the Inclusion 
Visit  in % of worst score for total score, 
upper extremities subscore and mobility 
subscore using the adult form of the 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 14  
 
 Visit  and over time under palovarotene 
treatment;  FOP-PFQ for all participants, at each 
Follow -up Visit; 
• To describe the FOP healthcare utilization in 
patients with FOP  • Type and f requency of healthcare utilization  
• To describe the parameters of lung function 
(observed and % predicted forced vital 
capacity (FVC), observed and % predicted 
forced expi[INVESTIGATOR_31737] 
(FEV 1), absolute and predicted FEV 1/FVC 
ratio, observed and % predicted diffusion 
capacity of the lung for carbon monoxide 
(DLCO)) at the Inclusion Visit and over time 
under palovarotene treatment;  • Raw values and change from the Inclusion 
Visit in observed and % predicted FVC at each 
Follow -up Visit;  
• Raw values and change from the Inclusion 
Visit in observed and % predicted FEV 1 at 
each Follow -up Visit;  
• Raw values and change from the Inclusion 
Visit in absolute and predicted FEV 1/FVC 
ratio at each Follow -up Visit;  
• Raw values and change from the Inclusio n 
Visit in observed and % predicted DLCO at 
each Follow -up Visit;  
• To describe physical and mental health, using 
the adult form of the Patient Reported 
Outcomes Measurement Information System 
(PROMIS) Global Health Scale, at the 
Inclusion Visit and over ti me under 
palovarotene treatment;  • Raw values and change from the Inclusion 
Visit in physical and mental function (mean 
global physical and mental health score 
converted into T -scores), using the adult form 
of the PROMIS Global Health Scale for all 
participa nts, at each Follow -up Visit;  
• To describe the number of 
investigator -reported flare -ups, flare -up 
outcomes ( extra  bone growth, restricted 
movement) and flare -up duration by [CONTACT_775968];  • Raw values and change from the Inclusion 
Visit in number of investigator -reported flare -
ups, flare -up outcomes ( extra  bone growth, 
restricted movement) and flare -up duration at 
each Follow -up Visit by [CONTACT_775969];  
• Percentage of participants with extra bone 
growth associated or not with a flare-up at 
each Follow -up Visit;  
In relation to FOP:  
• To further understand and describe 
participants’ experiences with FOP  symptoms 
(e.g. flare -ups, joints being locked );  
• To describe the overall impact of the disease 
on participants  living with FOP (e.g. physical  
functioning , emotional health , social  
functioning , work/school /daily life  impacts);  
• To identify and rank the critical joints from a 
participant’s perspective;  
 
In relation to patient experiences with palovarotene in 
the parent study:  
• To further u nderstand and describe 
participant experience with palovarotene (e.g. 
decrease in number of flares up, delay in 
physical disability, overall satisfaction) ; 
• To describe the emotional benefit for 
participants of using palovarotene as a 
treatment for FOP;  
• To assess participants’ perceptions of  benefits 
and risks of palovarotene.   • Not applicable.  
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 15  
 
 Overall Design : 
Study CLIN -[ADDRESS_1065780] completed one of the 
parent studies (Study  PVO -1A-301 or PVO -1A-202/PVO -1A-204) and , in the investigator’s 
judgement,  may benefit from palovarotene therapy.  Participants who have completed the parent 
study are defined as those who have completed  the p arent End of Study ( EOS ) or End of 
Treatment Visit.  
The study is designed primarily to further evaluate the safety of palovarotene and secondly, to 
collect efficacy data in male and female participants aged ≥14 years (qualifying as skeletally 
mature or, ba sed on investigator ’s assessment, have reached final adult height) with FOP treated 
with palovarotene.  Cross -sectional qualitative interviews will also be conducted  by [CONTACT_1961]  (PI)/qualified site staff , within 1  year (ideally within 1  month) following the 
Inclusion Visit , to inform on patient -centred  outcomes such as perception of living with FOP  
and perceived treatment benefit  of palovarotene . 
Participants are eligible for the study  whether they are rece iving chronic or flare -up treatment 
in the parent study at the time of transition. Participants who previously interrupted/stopped 
palovarotene treatment and are currently under parent study follow -up due to the premature 
physeal closure ( PPC) related part ial clinical hold in participants <14  years, are eligible for the 
study if they are ≥14  years of age and skeletally mature/have reached final adult height based 
on investigator’s assessment.  There must be a current parent study signed informed consent 
(ICF ) form for the participant to be eligible for Study CLIN -[ZIP_CODE] -452. 
A maximum of 87 participant s from studies PVO -1A-301, PVO -1A-202/PVO -1A-204 are 
eligible to be enrolled and will receive palovarotene once daily at the dose received during their 
participation in the parent study at the time of transition to Study CLIN -[ZIP_CODE] -452 or prior to 
interrupting/stoppi[INVESTIGATOR_775924].  
The study will consist of a n Inclusion Visit  (Day 1) (which ideally corresponds to the parent 
EOS Visit), a continuous dosing treatment period (including a Follow -up Visit every six 
months), and an EOS/Early Withdrawal (EW) Visit.  
Eligible participant s will ideally enter the study directly after completing the EOS Visit of the 
parent study (Study PVO -1A-301 or PVO -1A-202/PVO -1A-204) and the ICF is signed. Any 
study assessments already performed at the parent EOS Visit will serve as the Inclusion Visit  
assessment for Study CLIN -[ZIP_CODE] -452 (maximu m of one month allowed between the two 
visits) . Treatment initiation for Study CLIN -[ZIP_CODE] -452 should ideally concur with the EOS 
Visit and the study intervention administration schedule of the parent study in order to ensure 
palovarotene treatment continuity for both chronic and flare -up treatment.  
The Inclusion  and EOS/EW Visit can be an in-clinic visit  or performed remotely  per study 
protocol sc hedule . However, to enable continued access to  the Investigationa l Product and 
rollover of participants with impaired mobility [in the case(s) when , per investigator’s 
judgement , this is considered as beneficial for the participant’s medical condition ], the parent 
EOS  Visit , and consenting for CLIN -[ZIP_CODE] -452 and CLIN -[ZIP_CODE]-452 Inclusion Visit can be 
conducted remotely. In such case(s) , both parts  of remote consenting used by [CONTACT_779] – i.e., 
Informing/Consenting discussion and ICF signature [CONTACT_776033]/EC, and the 
investigator’s judgement should be suff iciently documented in the patient source notes. Follow -
up Visits can be either in -clinic or performed remote ly (e.g., at the participant’s home by 
[CONTACT_775970] -home services and/ or via video -conference or telephone contact [CONTACT_775971] ). In-depth qualitative interviews , conducted  in person  or by [CONTACT_775972]/qualified site staff  within 1 year (ideally within 1  month)  following  the Inclusion Visit , will 
be proposed to all participants . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 16  
 
 Patient -reported questionnaires (FOP -PFQ, PROM IS Global Health Scale  and Healthcare 
Utilization ) will be completed by [CONTACT_775973] . All other data collected in the study 
will be recorded in an electronic case report form  (except for qualitative participant  interview 
data) .  
Participants will continue to receive palovarotene until it is reimbursed  in the country where 
the study is being conducted, or another access programme becomes available, or until the study 
end date of November [ADDRESS_1065781] if it is  allowed within the local laws, rules and regulations or 
specifically approved in writing by [CONTACT_50844].  
Participants can voluntarily withdraw from the study at any time for any reason.  
The study intervention can be discontinued for individual parti cipants by [CONTACT_105250]/she believes the participants’ safety is at risk.  
In the event of early study withdrawal or early discontinuation of the study intervention, all 
reasonable efforts should be made by [CONTACT_775974]-clinic or remotel y to have the 
participants complete all study assessments of the EW Visit as per the schedule of activities . 
Participants will be followed -up in-clinic or remotely for safety for [ADDRESS_1065782] 
palovarotene dose of the study is received . If the study intervention was discontinued due to a 
safety concern , in the case of an adverse event ( AE)/serious adverse event  (SAE) , the participant 
will be monitored until resolution, stabilisation or lost to follow -up and, in the case of 
pregnancy, the participant will be  followed throughout the pregnancy and the health status of 
the baby [CONTACT_775975].  
An Independent Data Monitoring Committee will be set -up. 
 
Intervention Groups  and Duration : 
This is a  noncomparative rollover study.  
Participants are eligible for the study whether they are receiving chronic or flare -up treatment 
in the parent study at the time of transition. Participants who previously interrupted/stopped 
palovarotene treatment and are currently under parent study follow -up are also eligible if they 
meet eligibility criteria. The dose of palovarotene  administered will be individualised for each 
participant and  based on the regimen  (chronic or flare -up treatment) , the dose received during 
their participation in the parent study at the time of transition to Study CLIN -[ZIP_CODE] -452 or prior 
to interrupting/stoppi[INVESTIGATOR_775925] (to allow for dose modifications made to the 
standard chronic/flare -up regimen during the parent study) . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 17  
 
 Chronic/flare -up regimen:  
Chronic tre atment:  oral palovarotene once daily , 5 mg , or at the dose received during 
participation in the parent study at the time of transitio n Study CLIN -[ZIP_CODE] -452 or prior to 
interrupting/stoppi[INVESTIGATOR_775925] . 
Flare -up treatment:  increase in dose at the time of a flare -up (or substantial high risk traumatic 
event likely to lead to a flare -up) to 20 mg once daily for 4 weeks  (28 days ), followed by 10 mg 
once daily for 8 weeks (56 days) for a total of 12 weeks (84 days) even if symptoms resolve 
earlier.  
Participants receiving flare -up treatment at the time of transition to Study CLIN -[ADDRESS_1065783] symptom indicative of a FOP flare -up 
or substantial high risk traumatic event likely to lead to a flare -up. Participants will be instructed 
to report pote ntial flare -up symptoms to study site personnel. Symptoms of a FOP flare -up 
typi[INVESTIGATOR_775926], soft tissue swelling/inflammation, 
redness, warmth, decreased joint range of motion, and stiffness  (only one symptom is req uired 
to define a flare -up). If these symptoms are consistent with previous flare -ups, include a 
participant -reported onset date, and are confirmed by [CONTACT_775976] a 
flare-up, participants will be instructed to immediately begin flar e-up-based treatment.  
Chronic treatment should cease at the time of initiation of flare -up treatment, re -initiation of the 
chronic  daily treatment should occur after completion of the flare -up treatment.  
Flare -ups can occur in the absence of any apparent c ausative factor, but there is a high risk that 
substantial traumatic events (e.g. surgery, intramuscular immunisation, mandibular blocks for 
dental work, muscle fatigue, blunt muscle trauma from bumps, bruises, falls or influenza -like 
viral illnesses), can  lead to a flare -up and result in heterotopic bone formation. Flare -up based 
treatment should also be initiated if the investigator confirms the presence of a substantial 
high-risk traumatic event likely to lead to a flare -up. 
Persistent flare -up symptoms : treatment may be extended in 4 -week intervals with 10 mg 
palovarotene and continued until the flare -up symptoms resolve.  
Intercurrent flare -up: if the participant experience s an intercurrent  flare-up (new flare -up 
location or marked worsening of the orig inal flare -up) at any time during the flare-up treatment, 
then the 12 -week flare-up treatment should be restarted.  
In the case of any intolerable adverse reactions, the daily dose of the chronic/flare -up regimen 
can be reduced  (see Table  5). 
Flare -up only regimen:  
If the participant experiences intolerable adverse reactions while taking chronic daily treatment 
and dose reduction does not alleviate the adv erse reactions, then the participant may take 
palovarotene only at the time of flare -up (or substantial high -risk traumatic event).  
 
Visit Frequency:  
Every six months.  
 
Study Participant and Intervention Duration:  
Participants will enter ideally this study directly after completing  the parent EOS Visit  and 
continue to receive palovarotene until it is reimbursed  in the country where the study is being 
conducted, or another access programme becomes available, or until the study end date of 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065784] study visit (November 2021 to 
November 2024).  
 
Number of Participant s: 
A maximum of 87 participants from studies PVO -1A-301, PVO -1A-202/PVO -1A-204 are 
eligible to be enrolled.  
 
Statistical Methods:  
No formal statistical testing will be performed. All the analyses will be primarily descriptive in 
nature.  
The Inclusion Visit  is the first study visit (Day 1) and first administration of palovarotene in 
Study CLIN -[ZIP_CODE] -452 (and corresponds  ideally  to the EOS Visit of the parent study for 
assessments already performed in the parent study ). 
Sample Size determination  
No formal sample size calculations have been performed as the sample size is dependent on the 
number of participants in the parent studies who are eligible. A maximum of 87 particip ants 
from studies PVO -1A-301, PVO -1A-202/PVO -1A-204 are eligible to be enrolled.  
Primary Analysis  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) and will be classified by [CONTACT_11702] (PT) and system organ cl ass (SOC). 
Adverse events listings will be presented by [CONTACT_3445], SOC and PT.  
The incidence of all reported TEAEs, serious and nonserious treatment -related TEAEs, serious 
and nonserious TEAEs, TEAEs  leading to death and TEAEs leading to treatment 
discon tinuation will be tabulated separately. In addition, summary tables for TEAEs will be 
presented by [CONTACT_775977] (investigator -reported 
causality assessment).  
Secondary Analyses  
All statistical analyses will be descriptive. For descriptive analyses, summary statistics will be 
presented at each scheduled visit. Summary statistics will include sample size, number of 
available observations (N), number of missing observations (missing ), mean, 95% confidence 
intervals (CIs) of the mean/median, standard deviation, number of nonmissing  observations (n), 
median and range for continuous variables and scores. For categorical or discrete variables, the 
absolute and relative (percentage) numbe rs based on the nonmissing number of observations 
for each category will be presented, including 95% CIs.  
Participant  Interview Analyses  
Participant  interviews will be performed within 1 year (ideally within 1  month) following the 
Inclusion Visit . No forma l hypotheses will be tested given the qualitative nature of the analyses.  
Initial thoughts will be recorded from each of the completed interviews. Key concepts raised 
by [CONTACT_775978], with a particul ar focus 
on the study objectives and other potential insights emerging from the interviews. Additionally, 
once the interview transcripts are available, the interview data will be analysed according to the 
final qualitative analysis plan, using a thematic q ualitative data analysis approach.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 19  
 
 All qualitative and limited quantitative data will be summarised descriptively. Where 
applicable, Ns and % s will be provided.  
Tables displaying the concepts described during the interviews will be developed to document 
the results of the interviews. Additionally, descriptive statistics based on the quantitative data 
obtained during the interviews (e.g. symptom improvements during the clinical study) will be 
computed and summarised.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 20  
 
 1.2 Schema  
Figure  1 Study Schema  
 
 
 
1.3 Schedule of Activities  
The schedule of activities (SoA) planned in this study are presented in Table  1.  
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 21  
 
 Table  1 Schedule of Activities  
Assessment/Procedure  Inclusion Visit[ a] 
Day 1  Follow -Up Visits  
Every 6 months (±1 
month)[ b]/ 
EOS/EW Visit[ c] 
 
 Procedures 
already 
performed at 
the parent 
EOS Visit 
that will be 
transferred 
from parent 
study 
database  Procedures 
already 
performed 
at the parent 
EOS Visit 
to be 
entered in 
CLIN -
[ZIP_CODE] -452 
eCRF by 
[CONTACT_775979] -
[ZIP_CODE] -452 
Inclusion 
Visit  In-clinic Visit  Remote visit  
Informed consent[ d]   X   
Inclusion/exclusion criteria    X   
Study intervention 
administration/accountability[ e]   X X X 
Baseline demographics    X   
Physical examination    X   
Participant interview[ f]   X   
Pregnancy testing and 
childbearing potential [ g]  X[a]*  X X 
Linear height and body weight 
[h]  X[a]*  X X 
Vital signs [ i]   X[a]*  X X 
Spi[INVESTIGATOR_775927] [j]  X [a]**  X  
Lung function assessments [ k]   X X  
Flare -up assessment [ l]   X X X [m] 
Additional Extra bone growth 
assessment (without associated 
flare-up)   X X X 
CAJIS  [n] X*   X X 
C-SSRS [ n] [o]   X X X 
FOP-PFQ assessment[ p] [q] X*  X [q]*** X X 
PROMIS Global Health Scale 
[p][q] X*  X [q]*** X X 
FOP assistive devices 
assessment [ p]   X X X 
Healthcare Utilization [ p]   X X X 
Biochemistry (amylase, lipase, 
AST, ALT) and triglycerides  X*     
Disease and flare -up history  X     
Prior medications  X     
Concomitant medications   X  X X 
Concomitant procedures [ r]  X  X X 
AEs [ s]  X  X X 
AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CAJIS=Cumulative Analogue Joint 
Involvement Scale for FOP; COVID -19=coronavirus disease 2019; C -SSRS= Columbia -Suicide Severity Rating Scale; 
DLCO=diffusion capacity of the lung for carbon monoxide; eCRF=electronic case report form; EOS=End of Study; 
EW=Early Withdrawal; FEV 1=forced  expi[INVESTIGATOR_31737]; FVC=forced vital capacity; FOP=fibrodysplasia 
ossificans progressiva; FOP -PFQ=FOP Physical Function Questionnaire; PROMIS=Patient Reported Outcomes 
Measurement Information System.  
a. The Inclusion Visit should be in -clinic and corresponds ideally to the EOS Visit of the parent study (Study PVO -1A-
301 or PVO -1A-202/PVO -1A-204). A maximum of one month is allowed between the two visits. For any assessments 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 22  
 
 from the parent EOS Visit performed outside this allowed ti me window, assessments will need to be performed again 
at the Study CLIN -[ZIP_CODE] -452 Inclusion Visit (flagged with *). However, to enable continued access to the  
Investigational Product and rollover of participants with impaired mobility [in the case(s) when  per investigator’s 
judgement this is considered as beneficial for the participant’s medical conditions ], the parent EOS  Visit and  
consenting for CLIN -[ZIP_CODE] -452 and CLIN -[ZIP_CODE] -452 Inclusion Visit can be conducted remotely. In such case(s) both 
parts  of rem ote consenting used by [CONTACT_779] – i.e. Informing/Consenting discussion and ICF signature [CONTACT_776034]/EC, and the investigator’s judgement should be sufficiently documented in the patient source notes.  
For the spi[INVESTIGATOR_775927] , a time window of [ADDRESS_1065785] parent visit is allowed (flagged with **).  
b. Follow -up Visits will be either in -clinic or performed remotely (e.g. at the participant’s home by [CONTACT_775970]-home 
services , and/or via video -conference or telephone contact [INVESTIGATOR_39736] m clinical site personnel).  
c. The EOS/EW Visit will be ideally an in -clinic visit (or remotely when permitted by [CONTACT_1201]/IEC) and will occur at the 
time of last study intervention intake. The EOS Visit must take place before the participant transitions to c ommercial 
treatment.  
d. For participants <18 years, assent and legal guardian’s consent will also be required.  
e. Palovarotene status (treated or not treated) and regimen (chronic or flare -up treatment) at the time of transition to Study 
CLIN -[ZIP_CODE] -452 will be c ollected at the Inclusion Visit. Participants will be supplied with chronic treatment as well 
as the appropriate dose of palovarotene to initiate flare -up treatment when a flare -up or traumatic event is confirmed 
by [CONTACT_093]. Participants will be i nstructed to report potential flare -up symptoms to study site personnel, only 
one symptom is required to define a flare -up (see Section 6.1). In the presence of persistent flare -up symptoms, 
treatment may be extended in 4 -week intervals until the flare -up symptoms resolve. If the participant experiences an 
intercurrent flare -up, or substantial high -risk traumatic event likely to lead to a flare -up, at any time during the flare -
up treatment, the 12 -week flare -up treatment should be restarted.  
f. Participant interviews will be conducted in person or by [CONTACT_775980]/ qualified site staff  and can be carried out 
anytime within 1 year (ideally within 1  month) following the Inclusion Visit.  
g. Participants will be assessed for child -bearing status and pregnancy prevention measures (females only). According to 
local practice, medically documented blood or urine pregnancy tests should be carried out prior to star ting therapy, 
monthly as long as the participant receives palovarotene and one month after stoppi[INVESTIGATOR_007] (the results of pregnancy tests 
will be recorded in the eCRF). See Section 8.2.[ADDRESS_1065786]  be perfor med at the Study CLIN -[ZIP_CODE] -452 Inclusion Visit  ONLY  if not already 
performed within  the time window allowed  (ie,, [ADDRESS_1065787]-parent EOS Visit ). The spi[INVESTIGATOR_775928] . The s pi[INVESTIGATOR_775929] (e.g. , CT, 
x-ray, scint igraphy , etc). This assessment may be performed locally.  
k. Includes spi[INVESTIGATOR_775930]. Spi[INVESTIGATOR_775931] % predicted 
FVC and FEV 1 and the absolute and predicted FEV 1/FVC ratio. The DLCO test obtains observed and % predicted 
DLCO which provides information on the efficiency of gas transfer from al veolar air into the bloodstream.  
l. Includes extra bone growth assessment when  associated  with a flare-up 
m. During remot e visit performed at home by [CONTACT_775981] -home services, the participant will be asked if any flare -ups 
occurred since last visit. If yes, the homecare clinician will attempt to facilitate a call between the participant and the 
site to provide details . 
n. In case of remote visit, the CAJIS and C -SSRS will be assessed via video -conference if possible or feasible or 
telephone contact [CONTACT_775982] e personnel . The homecare clinician will facilitate the call between the participant 
and Investigator.  
o. ‘Baseline’ version of C -SSRS will be used at the Study CLIN -[ZIP_CODE] -452 Inclusion visit.  ‘Since Last Visit’ version of 
C-SSRS will be used at Follow -Up Visits.  
p. In case of remote visit, the questionnaires will be provided by [CONTACT_775981] -home services  and completed by [CONTACT_32346] . 
q. Paper patient -reported questionnaires. Questionnaires completed at the parent EOS Visit will be used for the Study 
CLIN -[ZIP_CODE] -452 Inclusion Visit . The adult form (developed for participants ≥15 years old) of the FOP -PFQ and 
PROMIS Global Health Scale will be used for all participants.  At in -clinic visits when multiple assessments are to be 
performed, the FOP -PFQ and the PROMIS G lobal Health Scale should be completed first, and in that order, before 
any other assessments are completed. Participants who completed the paediatric versions of the questionnaires at the 
EOS Visit of the parent study are required to complete the adult ve rsions of the questionnaires at the CLIN -[ZIP_CODE] -452 
Inclusion Visit (flagged with ***).  
r. Any vaccinations received during the study (including COVID -19) should be recorded as concomitant procedures.  
s. AEs first occurring during participation in the parent study and ongoing at the time of the Study CLIN -[ZIP_CODE] -452 
Inclusion Visit will be entered again in the Study CLIN -[ZIP_CODE] -452 eCRF.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 23  
 
 2 INTRODUCTION  
Palovarotene is an orally bioavailable retinoic acid receptor gamma (RARγ) selective agonist 
that is being develo ped by [CONTACT_775983] (HO) in adults 
and children with fibrodysplasia (myositis) ossificans progressiva (FOP).  
2.1 Study Rationale  
Currently there are no commercially available effective treatments to prevent the formation  of 
heterotopic bone in FOP. Therapeutic approaches are limited to symptom management and 
flare-up prevention ( Kaplan et al., 2019a ; Meyers et al., 2019 ). 
The clinical safety and efficacy of palo varotene in reducing new HO in FOP has been evaluated 
and demonstrated in:  
• Study PVO -1A-201 (complete), a phase II, randomised, double -blind, 
placebo -controlled study;  
• Study PVO -1A-202 (Part A and B complete, Part C and D complete ; Parts B , C and D 
corresp ond to Study PVO -1A-204 in [LOCATION_009]), an open -label extension of Study 
PVO -1A-201; 
• Study PVO -1A-301 (Part A, B and C complete ), a phase III, single -arm, open -label 
study.  
The aim of this study is to provide continued access to an effective treatment for FOP for which 
there is no alternative  once the ongoing clinical studies have ended . More specifically, the aim 
is to provide treatment continuity to participants who have completed one of the parent studies 
(Study PVO -1A-301 or PVO -1A-202/PVO -1A-204) and , in the investigator’s judgement,  may 
benefit from palovarotene therapy until palovarotene is reimbursed  in the country where the 
study is being conducted, or another access programme becomes available , or until the study 
end date of November [ADDRESS_1065788].  
2.2 Background  
2.2.1 Disease Background  
Fibrodysplasia ossificans progressiva  (Online Mendelian Inheritance in Man (OMIM) 
#135100) is an ultra -rare genetic disorder, with an estimated prevalence of 1.36 per million 
individuals ( Baujat et al., 2017 ). 
FOP is caused by a spontaneous missense mutation in the activin A receptor type -1 
(ACVR1 )/activin receptor -like-kinase -2 (ALK2 ) gene, which encodes a receptor in the bone 
morphogenetic protein (BMP) signalling pathway (Pi[INVESTIGATOR_775932]., 2013 ; Zhang et al., 2013 ). 
Bone morphogenetic proteins are extracellular ligands belonging to the transforming growth 
factor beta ( TGF -β) superfamily. Signal transduction studies show that receptor -regulated Smad 
proteins 1/5/8 are the immediate downstream molecules of BMP receptors and play a central 
role in BMP signal transduction ( Sanchez -Duffhues et al., 2016 ; Shen et a l., 2009 ). 
Following ligand binding to BMP receptors, there is downstream activation of genes involved 
in the differentiation and activation of osteoblast and chondrocyte -like cells via phosphorylation 
of Smad proteins 1/5/8; this is regulated by [CONTACT_775984] 12-kDa FK506 -binding protein 
(FKBP12 ), which binds to the BMP type 1 receptor and stabilises the inactive form 
(Sanchez -Duffhues  et al., 2016 ; Shen  et al., 2009 ). In the presence of the mutated ACVR1/ALK2  
gene, FKBP12 binding is reduced, leading to enhanced BMP signalling ( Sanchez -Duffhues et 
al., 2016 ). 
Patients with FOP experience sporadic and unpredictable epi[INVESTIGATOR_775933]‐tissue  swelling, pain, 
reduced movement, stiffness and fever, referred to as ‘flare‐ups ’ (Di Rocco  et al., 2017 ; 
Kaplan  et al., 2019a ; Pi[INVESTIGATOR_775932]., 2013 ; Pi[INVESTIGATOR_775932]., 2016 ). Flare‐ups appear spontaneously 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 24  
 
 or after muscle fatigue, minor trauma, intramuscular injections or influenza‐like viral illnesses, 
and develop rapi[INVESTIGATOR_775934] ( Kaplan et al. , 2019 a); these inciting events induce local 
inflammation, which is followed by [CONTACT_775985] ( Shimono et al., 2011 ). Although some flare -ups regress spontaneously, many 
appear to lead to HO, which transforms soft and connective tissues (including aponeuroses, 
fascia, ligaments, tendons and skeletal muscles) into heterotopic bone ( Kaplan et al., 2019a ; 
Pi[INVESTIGATOR_775932]., 2013 ). Of patients with FOP, 95% manifest HO before reaching 15 years of age 
(Qi et al., 2017 ). 
FOP is characterised by [CONTACT_775986] ; it is a severely disabling HO disorder ( Baujat et al., 2017 ; 
Pi[INVESTIGATOR_775935]., 2016 ). Other clinical features observed in patients with FOP are shortened 
thumbs, cervical spi[INVESTIGATOR_775936], short broad femoral necks and proximal medial tibial 
osteochondromas  (Kaplan et al., 2009 ; Pi[INVESTIGATOR_775935]., 2013 ). Typi[INVESTIGATOR_897], HO begins in the dorsal, 
proximal, axial and cranial regions of the body (ne ck, shoulders and back) and progresses into 
ventral, caudal and distal regions (trunk and limbs)  (Hüning and Gillessen -Kaesbach, 2014 ). 
Heterotopic ossifications develop into ribbons, sheets and plates of extra bone throughout  the 
body and across joints, thereby [CONTACT_775987]  (Baujat et al., 2017 ). Once 
ossification occurs, it is permanent; consequently, disability in FOP is cumulative, with most 
patients becoming immobilised a nd confined to a wheelchair by [CONTACT_775988]  (ADL) (Baujat et al., 2017 ; 
Mattera  et al., 2015 ; Ortiz -Agapi[INVESTIGATOR_775937] -Bonilla, 2015 ; Pi[INVESTIGATOR_775935]., 2013 ; 
Pi[INVESTIGATOR_775932]., 2020 a). 
FOP is not only an extremely disabling disease but also a condition of consi derably shortened 
lifespan ( Kaplan et al., 2010 ). Morbidity associated with FOP includes fractures (due to the 
increased risk of falls, immobility and prednisone use), limb swelling, pressure sores, hearing 
impairment, gastroi ntestinal issues and pain ( Kaplan et al., 2019b ; Peng et al., 2019 ). Patients 
with FOP reach a median survival of 56 (95% confidence interval ( CI): 51; 60) years; death is 
often due to cardiorespir atory failure (as a result of respi[INVESTIGATOR_5448], which is usually 
caused by [CONTACT_775989] -wall HO) or thrombosis ( Baujat et al., 2017 ; 
Di Rocco  et al., 2017 ; Kaplan et al., 2010 ; Pi[INVESTIGATOR_775935]., 2013 ). 
There are currently no effective treatments to prevent the formation of heterotopic bone in FOP, 
with therapeutic approaches being limited to symptom management and  flare-up prevention; 
consequently, there is a critical unmet need for definitive therapi[INVESTIGATOR_775938] 
(Kaplan et al., 2019a ; Meyers et al., 2019 ). 
2.2.[ADDRESS_1065789].  
RARγ is a nuclear hormone receptor that has a role in regulating skeletal development and 
growth; it is expressed in chondrogenic cells and chondrocytes ( Koyama et al., 1999 ), wh ere it 
operates as a transcriptional repressor ( Williams, et al., 2009 ). Activation of the retinoid 
signalling pathway and RARγ has been demonstrated to inhibit both chondrogenesis and HO 
(Kapl an et al., 2017 a). Given that chondrogenesis requires a decrease in retinoid signalling 
concurrent with upregulation of pro -chondrogenic pathways, including BMP signalling 
(Weston et al., 2002 ; Hoffman et al., 2006 ), RARγ agonists are likely to elicit anti -chondrogenic 
and anti -HO effects by [CONTACT_775990] 
(Shimono et al., 2011 ).  
RARγ agonists potently impede heterotopic endochondral ossification by [CONTACT_775991] (namely Smad 1/5/8) of the mutated ACVR1/ALK2  gene and by 

[CONTACT_775992] -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065790] fate to a nonosseous 
soft‑tissue fate ( Shimono et al., 2011 ; Kaplan et al., 2011 ). 
Palovarotene has been found to reduce new HO in animal models, and participants with FOP 
in phase II and III studies. A brief summary of clinical safety and efficacy of palovarotene in 
participants aged ≥8/10 years is provided in the sections that follow. To note, the target 
population for this study is ≥14 years  which is aligned with the age of treated participants in th e 
completed  parent studies (Study PVO -1A-301 and PVO -1A-202/PVO -1A-204). A detailed 
description of the chemistry, pharmacology, nonclinical and clinical efficacy and safety of 
palovarotene is available in the Investigator’s Brochure  (IB). 
2.2.[ADDRESS_1065791] exposure to palovarotene in a total of 
164 participants, including 139 participants aged 8 years and above for females and 10 years 
and above for males (≥8/10 years) for a mean duration of 94. 1 weeks, to a maximum of 
3.8 years. Participants received either:  
• chronic/flare -up regimen : 5 mg daily dose of palovarotene with a 20/10 mg dose for 
12 weeks at the time of flare -up (4 weeks of 20 mg once daily followed by 10 mg once 
daily for 8 weeks);  
• flare-up regimen only:  either the 20/10 mg dose for 12 weeks, a 10/5 mg dose for 6 weeks 
(10 mg once daily for 2 weeks followed by 5 mg once daily for 4 weeks) or a 5/2.5 mg 
dose for 6 weeks (5 mg once daily for 2 weeks followed by 2.5 mg once daily for 
4 weeks).  
In palovarotene -treated participants aged ≥8/[ADDRESS_1065792] commonly reported adverse 
reactions were in the Skin and subcutaneous disorders  (98.8%), Gastrointestinal disorders  
(86.6%) and Infections and infestations  (82.3%) System Organ Classes (SOC). The majority of 
adverse events (AEs) were mild or moderate ( 19.5% and 56.7% of participants, respectively) 
across all palovarotene FOP studies.  
Serious adverse reactions reported in palovarotene -treated participants aged ≥8/10 years 
included PPC (pr eferred term (PT) : epi[INVESTIGATOR_775939]) and cellulitis ( 13 participants 
each; 1. 2%).  
Adverse events leading to permanent discontinuation occurred in 9.8% of palovarotene -treated 
participants aged ≥8/10 years. No study discontinuations were reported  in placebo/untreated 
participants due to AEs. Mucocutaneous AEs leading to dose reductions were more common 
during palovarotene 20/10  mg flare -up treatment than during chronic treatment.  
Participants <18 years with open epi[INVESTIGATOR_775940].  
Twenty -seven  of 87 skel etally immature FOP participants <[ADDRESS_1065793] 
physiologic growth plate closure. Thus, any narrowing, partial closure, or closure are likely  to 
be assessed as premature by [CONTACT_15370]. However, the possibility that younger participants 
with specific risk factors are predisposed to developi[INVESTIGATOR_775941].  
No pregnancies or deaths  were reported during the clinical development programme. One death, 
due to restrictive lung disease from complications of FOP, occurred two and a half months after 
discontinuing palovarotene treatment.  Efficacy of Palovarotene  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 26  
 
 2.2.4 Efficacy of Palovarotene  
[IP_ADDRESS]  Phase II Studies  
The flare -up only regimen was assessed in the phase II programme, including the double -blind, 
placebo -controlled Study PVO -1A-201 and the open -label extension, Study PVO -1A-202. 
In Study PVO -1A-201, participants  were randomi sed in a 3:3:2 fas hion to palovarotene  10 mg 
for 2 weeks, then 5 mg for 4 weeks (10/5 mg treatment), palovarotene  5 mg for 2 weeks, then 
2.5 mg for 4 weeks (5/2.5 mg treatment), or placebo for 6 weeks, followed by a 6 -week 
observation period for all groups. The clinical end point of mean volume of new HO following 
a flare -up at Week 12 in evaluable flare -ups was assessed.  
In Study PVO -1A-202 Part A, participants experiencing another flare -up received palovarotene 
10/[ADDRESS_1065794] 90% 
skeletally mature received chronic 5 mg daily treatment with increased dosing at the time of a 
flare-up to 20 mg for 4 weeks followed by 10 mg for 8 weeks (chronic/flare -up regimen), with 
continuation of treatment in 4 -week increm ents for persistent symptoms. Skeletally immature 
participants received the 20/10 mg flare -up treatment (weight -adjusted) in Part B.  
The comparator group includes flare -ups imaged in untreated participants  from the Natural 
History Study ( NHS ) (an internati onal, 3 -year, longitudinal, noninterventional study)  and 
placebo -treated flare -ups from Study PVO -1A-201. These two sources of participants  were 
similar with respect to demographics and baseline disease characteristics.  
Based on pooled data from Studies PV O-1A-201, PVO -1A-202/Parts A and B, and PVO -1A-
001 (NHS), there was a statistically significant 72% decrease (approximated P value of 0.02) 
in the new HO volume in the 15 flare -ups treated with the 20/10 -mg flare -up only regimen 
(3045 mm3) compared with the volume observed in untreated/placebo flare -ups (10,780 mm3).  
Combining all flare -ups treated with the 20/10 -mg regimen, regardless of whether they were 
preceded by [CONTACT_775993] 5 mg, resulted in a 55% reduction in new HO (4818 mm3 
in 48 flar e-ups) relative to untreated/placebo flare -ups (approximated P value of 0.24) . 
[IP_ADDRESS]  Phase III Study  
The phase III study, PVO -1A-301, evaluated the efficacy and safety of the chronic/flare -up 
palovarotene treatment regimen in preventing new HO as compared to dat a from the NHS . 
Participants received palovarotene [ADDRESS_1065795] one symptom (e.g. pain, swelling, redness) consistent with a previous flare -up 
or a substantial high -risk traumatic event like ly to lead to a flare -up to 20 mg once daily for 
4 weeks followed by 10 mg once daily for 8 weeks (denoted as the chronic/flare -up regimen), 
with flare -up treatment extension in 4 -week increments for persistent symptoms. Anytime 
during flare -up treatment, the 12 -week treatment restarted if the participant had another flare -up 
or substantial high -risk traumatic event. The dosing was adjusted according to body weight in 
skeletally immature children (children who had not reached at least 90% skeletal maturity 
defined as a bone age of ≥12 years 0 months for girls and ≥14 years 0 months for boys).  
The treatment groups assessed in the chronic/flare -up regimen were well matched for baseline 
demographics.  
Post-hoc analyses showed that, f or participants aged ≥8/10 years, the mean annualised new HO 
volume was 56% lower in palovarotene -treated participants ( 11 419 mm3) (N=77) than that 
observed in untreated participants ( 25 796  mm3) (N=79). 
The weighted linear mixed effects analysis showed a 49% lower fitted mean annualised new 
HO volume in palovarotene treated participants ( 11 033  mm3) versus untreated participants in 
the NHS ( 21 476  mm3), yielding 2 -sided nominal p -value p= 0.1124 . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 27  
 
  
2.3 Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of palovarotene  may be found in the IB. 
2.3.[ADDRESS_1065796] of potential risks may be revised if necessary, 
according to each new IB version published during Study CLIN -[ZIP_CODE] -452. 
Table  2 Summary of Potential Risks of Study Participatio n and Mitigation Strategy  
Potential Risk of 
Clinical Significance  Summary of Data/Rationale for 
Risk  Mitigation Strategy  
Study Intervention  
Contraindications  
Teratogenicity   The teratogenic potential of systemic 
retinoids is well established 
regarding the risk to the developi[INVESTIGATOR_775942]. Although there 
were no pregnancies in the 
palovarotene development 
programme, findings in toxicology 
studies demonstrate characteris tic 
patterns of foetal  malformations 
typi[INVESTIGATOR_775943] (e.g. cleft palate, 
misshapen skull bones, short/long 
bones). At higher dosages, these 
effects resulted in reduced foetal  
survival. Similar to other systemic 
retinoids, palovarotene is assumed to 
be a potent teratogen and has the 
potential to adversely affect 
development of an embryo or foetus 
if given to a pregnant female patient 
and lead to adverse pregnancy 
outcomes.  Participant selection:  Participants who 
are pregnant or breastfeeding will not be 
included in  the study.  FOCBP are only 
eligible to participate in the study if they 
have met all the conditions of pregnancy 
prevention (Section  5.1). 
Participant monitoring:  During the 
study, pregnancy testing will be carried 
out monthly until one month after stoppi[INVESTIGATOR_206816] (Section  8.2.6 ). 
Study intervention w ithdrawal criteria:  
If a p articipant become s pregnant during 
the study , palovarotene will be 
immediately discontinued  (Section 8.3.5 ). 
Radiological vertebral 
fracture  In clinical trials, palovarotene has 
resulted in decreased vertebral bone 
mineral content, decreased bone 
density and decreased bone strength 
as well as an increased risk of 
radiologically observed vertebral (T4 
to L4) fractures in treated adult and 
paediatric patients compared with 
untreated patients.  Participant selection:  Participants who 
have any symptomatic vertebral fracture 
will not be included in the study (Section 
5.2). 
 
Instruction: Assessment of 25 -OH 
Vitamin D levels is recommended and  
supplementation with Vitamin D for good 
bone health should be considered as per 
the ICC on FOP guideline [ ICC FOP 
2022 ] and local guidelines.  
 
Participant monitoring: Spi[INVESTIGATOR_775944] (e.g., CT, x -
ray, scintigraphy, etc).  
 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 28  
 
 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for 
Risk  Mitigation Strategy  
Hypersensitivity to 
palovarotene  Not applicable  Participant selection: Participants with a 
known allergy to palovarotene  will not be 
included in  the study (Section  5.2). 
Participant monitoring:  During the 
study, participants will be monitored for 
signs of hypersensitivity/allergy and any 
event s will be recorded as AEs 
(Section  8.3). 
Study intervention w ithdrawal criteria:  
The daily dose of palovarotene can be 
reduced for any intolerable adverse 
effects. If already receiving the lowest 
dose, palovarotene can be temporarily or 
permanently discontinued or the 
participant switched to flare -up treatment 
only (Section  6.5). 
Special warnings and precautions for use 
Mucocutaneous effects  Mucocutaneous toxicities are the 
most common side effects of 
systemic retinoids and are generally 
treatable, dose -dependent, and 
reversible. The most frequently 
reported AEs during FOP clinical 
studies with palovarotene  were 
primarily mucocutaneous in nature, 
includ ing cheilitis/dry lips, dry skin, 
pruritus and alopecia , and were 
generally assessed as related to 
palovarotene.  Participant selection: Participants who 
were intolerant to prior treatment with 
palovarotene will not be included in  the 
study (Section  5.2). 
Instruction: Participants will  be 
instructed to utilise symptomatic therapy 
(e.g. analgesics, skin emollients, lip 
moisturisers, artificial tears, or other 
helpful treatments), to minimize these side 
effects, or as prophylaxis in the stud y. 
Participant monitoring:  During the 
study,  participants  will be monitored for 
signs of mucocutaneous effects and any 
events will be recorded as AEs 
(Section  8.3). 
Study intervention w ithdrawal criteria:  
The daily dose of palovarotene can be 
reduced for any intolerable adverse 
effects. If already receiving the lowest 
dose, palovarotene can be temporari ly or 
permanently  discontinued  or the 
participant switched to flare -up treatment 
only (Section  6.5). 
Photosensitivity  Photosensitivity reactions, such as 
exaggerated sunburn reactions (e.g. 
burning, erythema, blistering) 
involving areas exposed to the sun 
have been associated with the use of 
retinoids.  
Although palovarotene has not been 
proven to be phototoxic, 
precautionary measures for 
phototoxici ty are recommended.  Participant selection: Participants who 
were intolerant to prior treatment with 
palovarotene, or any other medical 
condition that would expose the 
participant to undue risk, will not be 
included in the study (Section  5.2). 
Instructions:  Participants should avoid 
excessive exposure to sun and use 
protection from sunlight when it cannot be 
avoided (use of sunscreens, protective 
clothing, and use of sunglasses).  
Participant monitoring:  During the 
study, participants will be monitored for 
signs of photosensitivity  and any events 
will be recorded as AEs (Section 8.3). 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 29  
 
 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for 
Risk  Mitigation Strategy  
Study intervention withdrawal criteria:  
The daily dose of palovarotene  can be 
reduced for any intolerable adverse 
effects. If already receiving the lowest 
dose, palovarotene can be temporarily or 
permanently discontinued or the 
participant switched to flare -up treatment 
only (Section  6.5). 
Psychiatric disorders  Systemic retinoids have been 
associated with psychiatric side 
effects, including depression, 
suicide, aggression and psychosis. 
During FOP clinical studies, AEs 
related to psychiatric disorders were 
reported in a third of all participants 
with irritability, anxiety and 
depressed mood reported most 
frequently.  Participant selection: Participants with 
suicidal ideation (type 4 or 5) or any 
suicidal behaviour at the Study CLIN -
[ZIP_CODE] -452 Inclusion Visit  defined by [CONTACT_941] 
C-SSRS , will not be included in the study  
(Section  5.2). 
Participant monitoring:  During the 
study , will be monitored appropriately and 
observed closely for suicidal ideation and 
behaviour or any other unusual changes in 
behaviour  and any events will be recorded 
as AEs  (Section  8.2.1 ). 
Study intervention w ithdrawal criteria:   
If participants experience signs of suicidal 
ideation or behaviour, consideration 
should be given to discontinuing the study 
intervention.  
AE=adverse event; C-SSRS=Columbia -Suicide Severity Rating Scale; EOS=End of Study; FOCBP= female  
of childbearing potential ; FOP=fibrodysplasia ossificans progressiva.  
2.3.[ADDRESS_1065797] demonstrated reduction in HO 
formation.  
Therefore, the benefit afforded to participants with FOP enrolled in this study is continued 
access to a  definitive, effective treatment for FOP for which there is no alternative, until 
palovarotene is reimbursed  in the said participants country  or another  access programme 
becomes available .  
2.3.3 Overall Benefit: Risk Conclusion  
Taking into account the measures taken to minimi se risk to participants, the potential risks 
identified in association with palovarotene are justified by [CONTACT_775994] m ay be 
afforded to participants with  FOP. 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 30  
 
 3 OBJECTIVES AND ENDPOINTS  
Table  3 Objectives and Endpoints  
Objectives  Endpoints  
Primary   
• To further evaluate the safety of palovarotene 
in adult and paediatric participants with FOP.  • Incidence and description of all treatment -
emergent adverse events ( TEAEs) whether or 
not they are considered as related to the study 
intervention;  
• Incidence and description of all serious and 
nonserious treatment -related TEAEs;  
• Incidence and description of all serious 
TEAEs, whether or not they are considered as 
related to the study intervention;  
• Incidence and description of all nonserious 
TEAEs whether or not they are considered as 
related to the study intervention.  
Secondary   
• To describe range of motion, as assessed by 
[CONTACT_775966] (CAJIS) for FOP, at the Inclusion Visit  
and over time under palovarotene treatment;  • Raw values and change from the Inclusion 
Visit  in CAJIS total score at each Follow -up 
Visit; 
• To describe the use of assistive devices and 
adaptations for daily living by [CONTACT_775967], at the Inclusion Visit and over 
time under palovarotene treatment;  • Raw values and shift from the Inclusion Visit 
in the use of assistive devices and adaptations 
for daily living at each Follow -up Visit;  
• To describe physical function, using the adult 
form of the FOP Physical Function 
Questionnaire (FOP -PFQ), at the Inclusion 
Visit  and over time under palovarotene 
treatment;  • Raw values and change from the Inclusion 
Visit  in % of worst score for total score, upper 
extremities subscore and mobility subscore 
using the adult form of the FOP -PFQ for all 
participants, at each Follow -up Visit; 
• To describe the FOP healthcare utilization in 
patients with FOP  • Type and f requency of healthcare utilization  
• To describe the parameters of lung function 
(observed and % predicted forced vital 
capacity (FVC), observed and % predicted 
forced expi[INVESTIGATOR_31737] 
(FEV 1), absolu te and predicted FEV 1/FVC 
ratio, observed and % predicted diffusion 
capacity of the lung for carbon monoxide 
(DLCO)) at the Inclusion Visit  and over time 
under palovarotene treatment;  • Raw values and change from the Inclusion 
Visit  in observed and % predict ed FVC at each 
Follow -up Visit; 
• Raw values and change from the Inclusion 
Visit  in observed and % predicted FEV 1 at each 
Follow -up Visit; 
• Raw values and change from the Inclusion 
Visit  in absolute and predicted FEV 1/FVC ratio 
at each Follow -up Visit; 
• Raw values and change from the Inclusion 
Visit  in observed and % predicted DLCO at 
each Follow -up Visit; 
• To describe physical and mental health, using 
the adult form of the Patient Reported 
Outcomes Measurement Information System 
(PROMIS) Global Health Sc ale, at the 
Inclusion Visit  and over time under 
palovarotene treatment;  • Raw values and change from the Inclusion 
Visit  in physical and mental function (mean 
global physical and mental health score 
converted into T -scores), using the adult form 
of the PROMI S Global Health Scale for all 
participants, at each Follow -up Visit; 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 31  
 
 • To describe the number of 
investigator -reported flare -ups, flare -up 
outcomes ( extra bone growth, restricted 
movement) and flare -up duration by [CONTACT_775968];  • Raw values and c hange from the Inclusion 
Visit  in number of investigator -reported flare -
ups, flare -up outcomes ( extra bone growth, 
restricted movement) and flare -up duration at 
each Follow -up Visit by [CONTACT_775969];  
• Percentage of participants with extra bone 
growth associated or not with a  flare-up at each 
Follow -up Visit; 
In relation to FOP:  
• To further understand and describe 
participants’ experiences with FOP  
symptoms (e.g. flare -ups, joints being 
locked );  
• To describe the overall impact of the disease 
on participants living with FOP (e.g. physical 
functioning, emotional health, social 
functioning, work/school/daily life impacts);  
• To identify and rank the critical joints from a 
participant’s perspective;  
 
In relation to patient experiences with p alovarotene in 
the parent study:  
• To further understand and describe 
participant experience with palovarotene (e.g. 
decrease in number of flares up, delay in 
physical disability, overall satisfaction) ; 
• To describe the emotional benefit for 
participants of using palovarotene as a 
treatment for FOP;  
• To assess participants’ perceptions of benefits 
and risks of palovarotene.  • Not applicable.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065798] completed one of the 
parent studies (Study  PVO -1A-301 or PVO -1A-202/PVO -1A-204) and , in the investigator’s 
judgement,  may benefit from palovarotene therapy . Participants who have completed the p arent 
study are defined as those who have completed  the parent End of Study ( EOS ) or End of 
Treatment Visit . 
The study is designed primarily to further evaluate the  safety  of palovarotene and secondly, to 
collect efficacy data in male and female  participan ts aged ≥14 years (qualifying as skeletally 
mature or, based on investigator ’s assessment, have reached final adult height) with FOP  treated 
with palovarotene . Cross -sectional qualitative interviews will also be conducted  by [CONTACT_1961] (PI)/ qualified site staff, within 1  year (ideally within 1  month) following the 
Inclusion Visit , to inform on patient -centred  outcomes such as perception of living with FOP 
and perceived treatment benefit of palovarotene.  
Participants are eligible for the study whether they are receiving chronic or flare -up treatment 
in the parent study at the time of transition. Participants who previously interrupted/stopped 
palovarotene treatment and are currently under parent study follow -up due to the PPC related 
partial clinical hold in participants <14  years, are eligible for the study if they are ≥14  years of 
age and skeletally mature/have reached final adult height based on investigator’s assessment.  
There must be a current parent stud y signed informed consent form (ICF) for the participant to 
be eligible for Study CLIN -[ZIP_CODE] -452. 
A maximum of 87 participants from studies PVO -1A-301, PVO -1A-202/PVO -1A-204 are 
eligible to be enrolled and will receive palovarotene once daily at the dose received during their 
participation in the parent study at the time of transition to Study CLIN -[ZIP_CODE] -452 or prior to 
interrupting/stoppi[INVESTIGATOR_775925] .  
The study will consist of a n Inclusion Visit  (Day 1) (which corresponds  ideally  to the parent 
EOS Visit), a continuous dosing treatment period (including a Follow -up Visit every six 
months), and an EOS /Early Withdrawal ( EW) Visit.  The study design is illustrated in Figure  1. 
Eligible participants will  ideally  enter the study directly after completing the EOS Visit of the 
parent study (Study PVO -1A-301 or PVO -1A-202/PVO -1A-204) and the ICF is signed . Any 
study assessments already performed at the parent EOS Visit will serve as the Inclusion Visit  
assessment for Study CLIN -[ZIP_CODE] -452 (maximum of one month allowed between the two 
visits) . For assessments not performed in the parent study (i.e. spi[INVESTIGATOR_038]),  assessments will be 
performed at the Study CLIN -[ZIP_CODE] -452 Inclusion Visit . 
Treatment initiation (at the Inclusion Visit ) for Study CLIN -[ZIP_CODE] -452 should ideally concur 
with the EOS Visit and the study intervention administration schedule of the parent stu dy in 
order to ensure palovarotene treatment continuity for both chronic and flare -up treatment.  
The Inclusion  and EO S/EW Visit can be an in -clinic visit  or performed remotely  per study 
protocol schedule .  However, to enable continued access to  the Investigational Product and 
rollover of participants with impaired mobility [in the case(s) when per investigator’s 
judgement this is considered as beneficial for the participant’s medical conditions ], the parent 
EOS, consenting for CLIN -[ZIP_CODE] -452 and CLIN -[ZIP_CODE] -452 Inclusion Visit can be conducted 
remotely. In such case(s) both parts  of remote consenting used by [CONTACT_779] – i.e. 
Informing/Consenting discussion and ICF signature [CONTACT_776033]/EC, and the 
investigator’s judgement should b e sufficiently documented in the patient source notes.  Follow -
up Visits can be either in -clinic or performed remotely  (e.g., at the participant’s home by 

[CONTACT_775992] -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065799] from clinical site 
personn el). In-depth qualitative interviews , conducted  in person or  by [CONTACT_775972]/qualified site staff  within 1 year (ideally within 1  month) following  the Inclusion Visit , will 
be proposed to all participants .  
Participants will undergo the procedures and assessments specified in the SoA ( Table  1). 
Patient -reported questionnaires (FOP -PFQ, PROMIS Global Health S cale, Healthcare 
Utilization  and FOP Assistive Device Assessment ) will be completed by [CONTACT_775995] . All other data collected in the study will be recorded in an electronic case report form 
(eCRF)  (except for qualitative participant  interview data).  
Participants will continue to receive palovarotene until it is reimbursed  in the country where 
the study is being conducted, or another access programme becomes available, or until the study 
end date of November [ADDRESS_1065800] if it is allowed within the local laws, rules and regulations or 
specifically approved in writing by [CONTACT_50844].  
Participants can voluntarily withdraw from the study at any time for any reason.  
The study intervention can be discontinued for  individual participants by [CONTACT_105250]/she believes the participants’ safety is at risk.  
In the event of early study withdrawal or early discontinuation of the study intervention, all 
reasonable efforts should be made by [CONTACT_393354]-clinic or remotely  to have the 
participants complete all study assessments of the EW Visit as per the SoA.  
Participants will be followed -up in-clinic or remotely  for safety  for [ADDRESS_1065801] 
palovarotene dose of the study is received . If the study  intervention was discontinued due to a 
safety concern, the participant will be monitored for safety (see Section 8.3.3  for follow -up of 
AEs/ serious adverse event s (SAEs ) and Section 8.3.5  for follow -up of pregnancies).  
The EOS for an individual participant will be the date of study comp letion  due to palovarotene 
becoming reimbursed  in the country where the study is being conducted, or another access 
programme becoming available, or the study end date of November [ADDRESS_1065802] study visit 
(November  2021 to November 2024).  
An Independent Data Monitoring Committee (IDMC)  will be set -up, as described in Section  
10.1.[ADDRESS_1065803] 
completed one of the parent studies (Study PVO -1A-301 or PVO -1A-202/PVO -1A-204) and , 
in the investigator’s judgement,  may benefit from palovarotene therapy until palovarotene is 
reimbursed  in the country where the study is being conducted, or another access programme 
becomes available.  
In addition, the study will primarily further evaluate the  safety of palovarotene  and secondly, 
collect efficacy data  in participants with FOP treated with palovarotene . Cross -sectional 
qualitative interviews will also be conducted  by [CONTACT_458] (PI)/ qualified site 
staff, within 1  year (ideally withi n 1 month) following the Inclusion Visit , to inform on 
patient -centred  outcomes such as perception of living with FOP and perceived treatment benefit 
of palovarotene.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065804] efficacy data which w as collected in 
the parent studies ; range of motion , physical impairment, physical and mental health and the 
number of flare -ups experienced  and their outcome  and duration.  As in the parent studies, range 
of motion  will be assessed  by [CONTACT_566882] , physical impai rment by [CONTACT_775996] -PFQ and physical and 
mental function by [CONTACT_775997].  
The CAJIS is a disease -specific,  objective measure of joint movement completed by [CONTACT_775998]. CAJIS scores have been shown to  provide an 
accurate and reproducible overview of total body and regional mobility burden of FOP that 
correlates with age and functional status  (Kaplan et al., 2017 b; Pi[INVESTIGATOR_775932]., 2019 ). 
The FOP -PFQ is a disease -specific patient -reported outcome measure of physical impairment. 
It was developed by [CONTACT_775999] (an Ipsen Company) based on the FDA Guidance for Industry, 
‘Patient Reported Outcome Measures: Use in Medical Product Development to Su pport 
Labeling Claims’ to assess the relationship between patient reports of physical impairment due 
to HO, thereby [CONTACT_566911] a clinically meaningful endpoint. FOP -PFQ scores 
have been shown to provide a consistent and reproducible measur e of physical function and 
ability to conduct ADL , correlated with age, functional status and HO volume ( Pi[INVESTIGATOR_775935]., 
2019 ; Pi[INVESTIGATOR_775932]., 2020b ). 
The PROMIS Global Health Scale is a patien t-reported outcome measure of physical and 
mental function.  HO burden substantially impacts quality of life and physical functioning. A 
strong, statistically significant association between  total PROMIS Global Health Scale score s 
and the number of anatomic  sites subjectively reported as being affected by [CONTACT_776000] . 
In addition, a statistically significant association between the total PROMIS score and the FOP -
PFQ has been shown. When stratified by [CONTACT_547], this relationship holds only for females 
(Pi[INVESTIGATOR_775932]., 2020c ). 
The lung function parameters of FVC, FEV 1 and FEV 1/FVC ratio as well as the DLCO, a 
measure of the efficiency of gas transfer from alveolar air into the bloodstream, has not been 
collected in previous clinical studies but will inform on the effect of palovarotene on lung 
function. Patients with FOP often experience respi[INVESTIGATOR_5448], which is usually caused 
by [CONTACT_775989] -wall HO and is often the cause of death  (Kaplan et al., 2010 ). 
Further information on the use of assistive devices and adaptation s for daily living will be 
collected using a list compi[INVESTIGATOR_775945] (IFOPA) of assistive devices and adaptations for daily living used by [CONTACT_776001]. 
The target population for this study is ≥14 years (at the time the informed consent is signed)  
which is aligned with the age of treated participants in the completed  parent studies 
(Study  PVO -1A-301 and PVO -1A-202/PVO -1A-204).  
4.2.1 Participant Input into Design  
None.  
4.3 Justification for Dose  
The proposed dosing for palovarotene consists of 5  mg once daily (chronic treatment) with an 
increase in dose at the time of a flare -up to 20 mg once daily fo r 4 weeks  (28 days) , followed 
by 10 mg once daily for 8 weeks (56 days) for a total of 12 weeks (84 days) (20/10 mg flare -up 
treatment) even if symptoms resolve earlier . In the presence of persistent flare -up symptoms, 
treatment may be extended in 4 -week intervals with 10 mg palovarotene and continued until 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 35  
 
 the flare -up symptoms resolve.  Should the participant experience an  intercurrent  flare-up (new 
flare-up location or marked worsening of the original flare -up) at any time during flare -up 
treatment, the flare-up 12 -week treatment should be restarted  (see Section 6.1). In the case of 
adverse reactions, the daily dose can be reduced (see Section 6.5). If dose reduction does not 
alleviate the adverse reactions, then the participant may take palovarotene only at the time of a 
flare-up (or substantial high-risk traumatic event) (Section see 6.1). 
Participants are eligible for the study whether they are receiving chronic or flare -up treatment 
in the parent study at the time of transition. Participants who previously interrupted/stopped 
palovarotene treatment and are currently under parent study follow -up are also eligible if they 
meet eligibility criteria . As this is a rollover study  with the aim of providing treatment 
continuity , the dose of palovarotene administered will be individualised for each participant 
and based on the regimen  (chronic or flare -up treatment) and dose they received during their 
participation in the parent study at the time of transition to Study CLIN -[ZIP_CODE] -452 or prior to 
interrupting/stoppi[INVESTIGATOR_775925] (to allow for dose modifications made to the 
standard chronic/flare -up during the parent study) . 
The proposed chronic/ flare-up regimen was selected based on nonclinical and clinical data.  
In a non -injury -based mouse model of FOP that recapi[INVESTIGATOR_775946], including spontaneous HO formation, chronic daily treatment with 
palovaro tene at a human equivalent dose (HED) of approximately 5  mg prevented HO 
formation.  Importantly, in this animal model, the dosing regimen did not impair long bone 
growth but partially normalised the abnormal growth plate histology and shortened long bones 
that are key phenotypic features of this model.  The results raised the possibility that chronic 
daily palovarotene dosing may be a major component of an optimised clinical dosing strategy.  
The rationale for increasing the chronic palovarotene dose at the t ime of a flare -up comes from 
nonclinical data from two different mouse models of FOP which demonstrated a dose -related 
decrease in HO volume; and suggested that flare-up-based  treatment using an HED of 20 mg 
may be necessary to optimally prevent HO following an injury (equivalent to a flare -up in 
humans).  
The chronic/flare -up regimen was assessed in Study PVO -1A-301. The flare -up only regimen 
was assessed in the phase II studie s PVO -1A-201 and PVO -1A-202. Both regimens were 
demonstrated to significantly reduce new HO volume versus untreated/placebo -treated 
participants (see Section  2.2.4 ) 
While it is recogni sed that flare -ups can occur in the absence of any apparent causative factor, 
there is a high risk that substantial traumatic events such as surgery, intramuscular 
immuni sations, mandibular blocks for dental work, muscl e fatigue, blunt muscle trauma from 
bumps, bruises, falls, or influenza -like viral illnesses can induce flare -ups and progressive HO 
formation  (Kaplan et al., 2008 ). In one survey of patients  with FOP , flare -ups were induced i n 
two-thirds of falls and resulted in permanent loss of movement in 93% of patients  
(Glaser  et al., 1998 ). Th erefore, flare -up-based treatment should also be initiated if the 
investigator confirms the presence of a substantial  high-risk traumatic event likely to lead to a 
flare-up. 
4.4 End of Study  Definition  
The EOS for an individual participant will be the date of study completion ; the participant is 
considered to have completed the study if he/she  has stopped study intervention due to 
palovarotene becoming reimbursed  in the country where the study is being conducted, or 
another access programme becoming available, or the study end date of November [ADDRESS_1065805].  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065806] participant in the study  (Last 
Participant  Last Visit (LPLV)) . 
Criteria for study intervention discontinuation and participant discontinuation/withdrawal from 
the study are described in Section  7.1 and Section  7.2, respectively. Loss to follow -up is 
described in Section  7.3. 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065807] fulfilled the inclusion and exclusion criteria for 
Study  PVO -1A-301 or PVO -1A-202/PVO -1A-204. 
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Participant has completed the EOS or End of Treatment Visit of Study PVO -1A-301 or PVO -
1A-202 (PVO -1A-202 Parts C and D correspond to Study PVO -1A-204 in [LOCATION_009]) and did not 
previously withdraw consent from any of the parent studies to be eligible for Study CLIN -
[ZIP_CODE] -452. 
In the investigator’s judgment, the participant may benefit from continued p articipation in a 
palovarotene study.  
Age 
1. Participant must be ≥14 years of age ( aligned with the age of treated participants in the 
ongoing parent studies PVO -1A-301 and PVO -1A-202/PVO -1A-204) and qualify as 
100% skeletally mature  (if <18  years, based on a ssessments carried out at parent EOS 
Visit ; if ≥18  years, automatically considered  100% skeletally mature ) or have reached 
final adult height based on investigator’s assessment *, at the time the Study CLIN -
[ZIP_CODE] -452 informed consent  is signed . 
*The above criteria can be reached at any point after parent study end  for the participant to be 
eligible for Study CLIN -[ZIP_CODE] -452, as long as it is prior to p alovarotene becoming reimbursed  
in the country where the study is being conducted . 
Sex 
2.  Male , or female  who is not pregnant or breastfeeding  and has met all of the following 
conditions:  
• Females of child -bearing potential (FOCBP) (defined in Section  10.2.1 ) must have 
a negative blood or urine pregnancy test (with sensitivity of at least 50  mIU/mL) 
prior to administration of palovarotene;  
• FOCBP must agree to remain abstinent from heterosexual sex during treatment 
and for one month after treatment or, if sexually active, to use two effective 
methods of birth control (described in Section  10.2.2 ) during and for one month 
after treatment;  
• Additionally, sexually active FOCBP must already be using two effective methods 
of birth control one month before treatment is to start;  
• Specific risk of  the use of retinoids during pregnancy, and the agreement to remain 
abstinent or use two effective methods of birth control will be clearly defined in 
the informed consent and the participant or legally authorised representatives (e.g. 
parents, caregivers or legal guardians) must specifically sign this section.  
Contraceptive use by [CONTACT_776002].  
Guidance for contraception and collection of  pregnancy information is provided in 
Section  10.2. 
Requirements for pregnancy testing are located in Section 8.2.6 . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 38  
 
 Informed Consent  and Assent  
3. Capable of giving signed informed consent or providing assent as described in 
Section  10.1.3 . 
5.2 Exclusion Criteria  
Participants will not be included in the study if any of the following criteria apply:  
Medical conditions  
1. History  of allergy  or hypersensitivity  to retinoids, gelatin, lactose (note that lactose 
intolerance is not exclusionary) or  palovarotene, or unresponsiveness to prior treatment 
with palovarotene.  
2. Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, 
metabolic, ophthalm ologic, immunologic, psychiatric, or other significant disease.  
3. Symptomatic vertebral fracture . 
4. Any other medical condition /clinically significant abnormalities  that would expose the 
participant to undue risk or interfere with study assessments.  
5. Amylase or  lipase >2× above the upper limit of normal (ULN) or with a history of 
chronic pancreatitis.  
6. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× 
ULN.  
7. Fasting triglycerides >400 mg/dL with or without therapy.  
8. Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit  as defined 
by [CONTACT_48649] -Suicide Severity Rating Scale  (C-SSRS) . 
Prior/concomitant therapy  (see Section 6.8) 
9. Current u se of vitamin A or beta carotene, multivitamins containing vitamin A or beta 
carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of 
these products during palovarotene tr eatment.  
10. Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the 
Inclusion Visit . 
11. Concurrent treatment with tetracycline or any tetracycline derivatives due to the 
potential increased risk of pseudotumor cerebri.  
12. Use of c oncomitant medications that are strong inhibitors or inducers of 
cytochrome  P450 (CYP450) 3A4 activity  (see Section 6.8 and 10.5); or kinase 
inhibitors such as imatinib . 
Other exclusion  criteria  
13. Palovarotene is reimbursed  in the country where the study is being conducted.  
14. Any reason that, in the opi[INVESTIGATOR_871], would lead to the inability of the 
participant and/or family to comply with the protocol.  
5.[ADDRESS_1065808] s 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 39  
 
 regulatory authorities. Minimal information includes date of informed consent, demography, 
reason for screen failure, eligibility criteria and any SAE  at the time . 
Indiv iduals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 40  
 
 6 STUDY INTERVENTION  AND CONCOMITANT THERAPY  
Study intervention is defined as the investigational intervention  intended to be administered to 
the study participant according to the study protocol.  
6.1 Study Intervention Administered  
The study intervention administered is palovarotene. Participants are eligible for the study 
whether they are receiving chronic or flare -up treatment in the parent study at  the time of 
transition. Participants who previously interrupted/stopped palovarotene treatment and are 
currently under parent study follow -up are also eligible if they meet eligibility criteria. As this 
is a rollover study with the aim of providing treatm ent continuity, the dose of palovarotene 
administered will be individualised for each participant and based on the regimen (chronic or 
flare-up treatment) and the dose they received during their participation in the parent study at 
the time of transition t o Study CLIN -[ZIP_CODE] -452 or prior to interrupting/stoppi[INVESTIGATOR_775947] (to allow for dose modifications made to the standard chronic/flare -up regimen during 
the parent study) . 
In the completed  parent studies PVO -1A-202/PVO -1A-204 and PVO -1A-301, participants 
receiv ed the chronic/flare -up regimen  detailed in Table  4 below  (or the weight -based equivalent 
for <90% skeletally immature participants) , with flare -up treatment extension in 4-week 
increments for persistent symptoms.  In Study PVO -1A-301, anytime during flare -up treatment, 
the 12 -week treatment restarts if the participant has another flare -up or a substantial high -risk 
traumatic event. In bo th parent studies, the daily dose of palovarotene c an be reduced i f the 
participant experience s AEs that are not tolera ted. 
Participants receiving flare -up treatment at the time of transition to Study CLIN -[ZIP_CODE] -452 will 
continue and complete the flare -up treatment  as was planned in the parent study. Chronic daily 
treatment  should then be re -initiated at 5 mg, or the dose received during participation in the 
parent study prior to the flare -up. 
Treatment initiation (at the Inclusion Visit ) for Study CLIN -[ZIP_CODE] -452 should ideally concur 
with the EOS Visit and the study intervention administration schedule of the parent study in 
order to ensure palovarotene treatment continuity for both chronic and flare -up treatment.  
Details of the study interven tion are provided in Table  4. 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065809] capsules, taken once daily as chronic/flare -up treatment  
Type  Drug  
Dose Formulation  Capsule  
Unit Dose Strength(s)  Each capsule contains 1 mg, 1.5 mg, 2.5 mg, 5 mg or 10 mg of palovarotene as  
active ingredient  
Dosage Level(s)  Chronic/flare -up regimen:  
Chronic treatment  
5 mg once daily ( or at the dose received during participation in the parent 
study at the time of transition to Study CLIN -[ZIP_CODE] -452, or prior to 
interrupting/stoppi[INVESTIGATOR_775925] ) 
Flare -up treatment  
20 mg once daily for 4 weeks (28 days)  
10 mg once daily for 8 weeks (56 days)  
Persistent flare -up symptoms:  extension of 10 mg once daily in 4 -week 
increments  
Intercurrent flare -ups (new flare -up location or marked worsening of 
original flare -up): 12 -week flare -up treatment should be restarted  
Chronic treatment:  once daily, 5 mg or  at the dose received during 
participation in the parent study at the time of transition to Study 
CLIN -[ZIP_CODE] -452 or prior to interrupting/stoppi[INVESTIGATOR_775925] . 
Flare -up treatment:  increase in dose at the time of a flare -up (or substantial 
high risk traumatic event likely to lead to a flare -up) to 20 mg once daily for 
4 weeks  (28 days) , followed by 10 mg once daily for 8  weeks (56 days) for a 
total of 12  weeks (84 days) (20/10 mg flare -up treatment) even if symptoms 
resolve earlier.  
Flare -up treatment should begin at the onset of the first symptom indicative of a 
FOP flare -up or substantial high -risk traumatic event likely to lead to a flare -up. 
Symptoms of a FOP flare -up typi[INVESTIGATOR_775948], soft tissue swelling/inflammation, redness, warmth, decreased joint range 
of motion, and stiffness. Chronic treatment shou ld cease at the time of initiation 
of flare -up treatment, re -initiation of the chronic  daily treatment should occur 
after completion of the flare -up treatment.  
Flare -ups can occur in the absence of any apparent causative factor, but there is 
a high risk th at substantial traumatic events (e.g. surgery, intramuscular 
immunisation, mandibular blocks for dental work, muscle fatigue, blunt muscle 
trauma from bumps, bruises, falls or influenza -like viral illnesses), can lead to a 
flare-up and result in heterotopi c bone formation. Flare -up treatment should be 
initiated at the time of such events.  
Persistent flare -up symptoms : treatment may be extended in 4 -week intervals 
with 10 mg palovarotene and continued until the flare -up symptoms resolve.  
Intercurrent flare -up: if the participant experience s an intercurrent  flare-up 
(new flare -up location or marked worsening of the original flare -up) at any time 
during the flare-up treatment, the n the 12 -week  flare-up treatment should be 
restarted.  
In the case of any intolerable adverse reactions, the daily dose of the 
chronic/flare -up regimen can be reduced (see Section 6.5). 
Flare -up only regimen:  
If the participant experiences intolerable adverse reactions while taking chronic 
daily treatment and dose reduction does not alleviate the adverse reactions,  then 
the pa rticipant  may take palovarotene  only at the time of flare -up (or substantial 
high-risk traumatic event).  
Route of Administration  Oral 
Use Active study intervention  
IMP and NIMP/AMP.  IMP 
Sourcing  Centrally by [CONTACT_776003] -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 42  
 
 Packaging and Labelling  Study intervention will be provided in bottle or blister packag ing: 
-  90 capsules packaged in a bottle  (1 mg, 1.5 mg, 2.5  mg, 5  mg and 
10 mg). 
- 14 capsules packaged in a blister ( 1 mg, 1.5  mg and 5  mg) 
- 15 capsules packaged in a bottle (5 mg) for US patients only.  
 
Each carton will be labelled as required per country requirement.  
Storage requirements  To be s tored at room temperature ( between 15°C and 30°C) and  protected from 
light and humidity.  
Former Name s/Alias(es)  None  
AMP=auxiliary medicinal product; FOP=  fibrodysplasia ossificans progressiva; IMP=investigational medicinal product; 
NIMP= non investigational  medicinal product.  
Participants will be instructed to report potential flare -up symptoms to study site personnel. 
Only one symptom is required to define a flare -up. If these symptoms are consistent with 
previous flare -ups, include a partic ipant -reported onset date, and are confirmed by [CONTACT_776004] a flare -up, participants will immediately begin flare -up-based 
treatment. Flare -up based treatment should also be initiated if the investigator confirms the 
presence of a s ubstantial high -risk traumatic event likely to lead to a flare -up. 
Based on clinical signs and symptoms as determined by [CONTACT_093], flare -up treatment may 
be extended in 4 -week intervals while on -treatment with 10 mg palovarotene and continue until 
the flare -up resolves and the 4 -week extension treatment has been completed.  
Participants will be supplied with chronic treatment as well as the appropriate dose of 
palovarotene  to initiate flare-up treatment when a flare -up or traumatic event is confirmed  by 
[CONTACT_093]  (during in -clinic or remote visit, or by [CONTACT_24646]) . 
Participant s will be instructed to contact [CONTACT_776005] . The investigator will asse ss the adverse 
reaction  and, if appropriate, will instruct the participant to reduce  the daily dose of palovarotene 
as described in Section 6.5. If the participant does not have the appropriate dose in his/her 
possession, the study site will make immediate arrangements to ship the appropriate 
palovarotene dose to the participant.  
Palovarotene should be taken with food preferably at the same time each day. Palovarotene may 
be swallowed whole, or capsules may be opened and the contents emptied onto a teaspoon of 
soft food and taken immediately.  
6.[ADDRESS_1065810] waste (e.g. a resealable bag).  
Palovarotene capsules may be opened, and the contents emptied on a teaspoon of soft food and 
taken immediately. If not taken immediately, it can be taken after a maximum of one hour after 
the sprinkling provided it was maintained at room temperature and not exposed to direct 
sunlight.  
• The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reporte d and resolved before use of the study intervention.  
• Only participants enrolled in the study may receive study intervention and only 
authori sed site staff may supply study intervention. All study intervention must be stored 
in a secure, environmentally con trolled and monitored (manual or automated) area in 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 43  
 
 accordance with the labelled  storage conditions with access limited to the investigator 
and authori sed site staff.  
• The investigator, institution or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(i.e. receipt, reconciliation and final disposition records).  
• The sponsor will provide guidance on the destruction of unused study intervention. If 
destruction is authorised to take place at the investigational site, the investigator must 
ensure that the materials are destroyed in compliance with applicable environmental 
regulations, institutional policy and any special instructions provided by [CONTACT_456]. All 
destruction must be adequately documented.   
Further guidance and information for the receipt,  preparation, management and disposal/return  
of the study intervention are provided in the ‘Investigational Medicinal Product Handling 
Manual ’. 
At each dispensation (at scheduled and unscheduled visits, if applicable), treatment number(s) 
will be assigned by [CONTACT_80356] (IWRS). The IWRS will also manage 
all logistical aspects of the study treatment (e.g. replacement, drug s upplies and expi[INVESTIGATOR_31637]) 
and the recording of drug accountability/destruction. This service provides the investigator , 
investigational site coordinators and project team members with a service that is available 
24 hours a day, 7  days a week. Additional de tails may be found in the IWRS reference manual 
provided to each investigational site. In case of technical or dispensation queries, a 24 -hour 
helpline is available. If a participant discontinues the study before any intake of study treatment, 
his/her assi gned treatment number(s) will not be reused.  
In addition to the information provided in the IWRS, drug accountability paper records will be 
maintained by [CONTACT_093].  
6.3 Measures to Minimi se Bias: Randomi sation and Blinding  
6.3.1 Randomisation  
Not applicable a s this is a nonrandomised study.  
6.3.2 Maintenance of Blinding  
This is an open -label study therefore no procedures for blinding are applicable.  
6.4 Study Intervention Administr ation/ Accountability  
Study intervention  bottles  and blisters  will be brought back to the s ite and accountability 
performed. Accountability  will be documented in the source documents and IWRS . 
A record of the quantity of palovarotene  dispensed to and administered  by [CONTACT_776006].   
Palovarotene status (treated or not treated) and regimen (chronic or flare -up or intercurrent  
flare-up or persistent flare up symptoms  treatment ) at the time of transition to Study 
CLIN -[ADDRESS_1065811] study site personnel immediately in case of intolerable 
adverse reactions  during palovarotene treatment . The investigator will assess the adverse 
reaction and, if appropriate, will instruc t the participant to reduce t he daily dose to the next 
lower dosage as shown in Table  5; additional dose reduction should occur if adverse reactions 
continue to be intolerable. If the pa rticipant  is already receiving the lowest possible dose, then 
consideration should be given to discontinue therapy temporarily or permanently or switching 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 44  
 
 to flare -up treatment only (see Section 6.1). Subsequent flare -up treatment should be initiated 
at the same reduced treatment that was tolerated previously.  
Table  [ADDRESS_1065812] completed one of the parent studies until palovarotene is reimbursed  in the country where 
the study is being conducted, or another access programme becomes available, or until the study 
end date of November 2024 is reached, at which point the study will end. Therefore,  participants 
will not receive any additional study intervention  following the EOS . 
6.7 Treatment of Overdose  
For this study, any dose of palovarot ene greater than those specified in Section 6.1 will be 
considered an overdose.  
The s ponsor does not recommend specific treatment for an overdose ; any overdose should be 
treated with supportive care according to the signs and symptoms exhib ited by [CONTACT_2299].  
In the event of an overdose, the investigator/treating physician should:  
• Contact [CONTACT_10990].  
• Evaluate the participant to determine, in consultation with the medical monitor, whether 
study intervention should be  interrupted or whether the dose should be reduced.  
• Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
palovarotene  can no longer be detected systemically (at least  30 days).  
• Document the quantity of the excess dose as well a s the duration of the overdose.  See 
Section  10.3.1  for reporting requirements concerning overdose.  
6.8 Prior and Concomitant Therapy  
The following medications are not allowed during palovarotene treatment (chronic or 
flare-up-based treatment):  
• Vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal 
preparations, or fish oil are not permitted from the day before the sta rt of treatment until 
the last day of treatment.  
• Synthetic oral retinoids other than palovarotene are not permitted in the [ADDRESS_1065813] day of treatment.  
• Concomitant use of tetracyclines and retinoids has been associated with b enign 
intracranial hypertension. Therefore, use of tetracycline or tetracycline derivatives is 
prohibited during the study. If the participant experiences a medical condition that 
requires treatment with tetracycline and/or doxycycline, the study intervent ion should be 
discontinued for the duration of tetracycline treatment and the medical monitor should 
be notified. Prior to restarting treatment with palovarotene, an appropriate wash -out 
period of [ADDRESS_1065814] be considered.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 45  
 
 • Strong inhibitors of CYP450 3A4 are known to alter the metabolism of palovarotene. 
Thus, concurrent oral medications identified as strong inhibitors of CYP450 3A4 (see 
Section  10.5) are excluded. If during the study, the participant  must take a strong inhibitor 
of CYP450 3A4, the study intervention  is to be discontinued for the duration of treatment. 
Prior to restarting treatment with palovarotene, an appropriate wash -out period (fiv e half -
lives) must be considered (see Section  10.5). 
• Strong inducers of CYP450 3A4 are also known to alter the metabolism of palovarotene. 
Thus, concurrent oral medications identified as strong inducers of CYP450  3A4 (see 
Section  10.5) are excluded. If during the study, the participant  must tak e a strong inducer 
of CYP450 3A4, the study intervention  may continue, but the medical monitor should be 
notified.  
• Kinase inhibitors such as imatinib, and other drugs used off -label as potential treatments 
for FOP such as rapamycin, as reported in the lite rature. A washout period of 5 half -lives 
is required prior to enrolment into the study.  
Prior medications will not be collected or recorded in the Study CLIN -[ZIP_CODE] -452 eCRF . These 
data will be transferred  from the final parent stud y database  and summarised  at the Inclusion 
Visit . 
Any medication (including over -the-counter or prescription medicines, recreational drugs, 
vitamins, herbal supplements  and vaccines (e.g. COVID -19)) or other specific categories of 
interest that the participant receives during the study will be collected at the Inclusion Visit , the 
Follow -up Visits and the EOS/EW Visit along with:  
• Reason for use ; 
• Dates of administration including start and end dates ; 
• Dosage information including dose and freq uency . 
The medical monitor should be contact[CONTACT_63193].  
The following data on concomitant procedur es will be collected at the Inclusion Visit  and at the 
Follow -up/EOS/EW Visits:  
• Surgical procedure n ame;  
• Indication;  
• Reason for concomitant surgery;  
• Date of surgery.  
6.8.1 Preventive Medication  
Assessment of 25 -OH Vitamin D  level is recommended and s upplementation with Vitamin  D 
for good bone health  should be considered as per  the ICC on FOP guideline [ ICC FOP 2022 ] 
and local guid eline s. 
6.8.[ADDRESS_1065815] 
frequently reported AEs during FOP clinical studies with palovarotene were primarily 
mucocutaneous in nature, including cheilitis/dry lips, dry skin, pruritus and alopecia, and were 
generally assessed as related to palovarotene.  
Participants will be instructed to utilise symptomatic therapy (e.g. analgesics, skin emollients, 
lip moisturiser s, artificial tears, or other helpful treatments), to minimize these side effects, or 
as prophylaxis in the studies.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 46  
 
 Although palovarotene has not been proven to be phototoxic, precautionary measures for 
phototoxicity are recommended. Participants should a void excessive exposure to sun and use 
protection from sunlight when it cannot be avoided (use of sunscreens, protective clothing, and 
use of sunglasses).  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 47  
 
 7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
Discontinuation of s pecific sites or of the study as a whole are detailed in Section 10.1.9 . 
7.1 Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention  before the EOS . Palovarotene treatment for individual participants can be 
discontinued by [CONTACT_087]/she believes the participants’ safety is at risk. In the event 
of pregnancy, pa lovarotene  treatment must be discontinued  (Section 8.3.5 ). 
If palovarotene is permanently discontinued, the participant will be withdrawn from the study.  
All reasonable efforts should be made by [CONTACT_776007] (see Table  1). 
If palovarotene  is permanently discontinued  due to a safety concern, the participant will be 
monitored for safety (see Section 8.3.3  for follow -up of AEs /SAEs  and Section 8.3.5  for 
follow -up of pregnancies ). 
7.1.[ADDRESS_1065816] possible dose (see Section 6.5), the participant  continues to 
experienc e intolerable adverse effect s. 
If palovarotene is temporarily interrupted, the participant will remain in the study and 
assessments performed as planned per the SoA.  
If palovarotene is permanently discontinued, the participant will be withdrawn from the study 
and all reasonable efforts should be made by [CONTACT_776008].  
In case of suspected or confirmed COVID -19 (SARS -CoV -2) infection, the intervention 
administration  may be temporarily discontinued depending on the participant clinical 
presentation. In some cases, the investigator may request a participant be retested before the 
intervention administration is resumed.  
7.1.4 Rechallenge  
If palovarotene is temporarily interr upted due to a  safety related event , once the event resolves, 
treatment can resume at the discretion of the investigator. If the event reoccurs, palovarotene 
treatment may be temporarily interrupted again or permanently discontinued.  
7.2 Participant Discontinu ation/ Withdrawal from the Study  
• A participant  may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator  for safety, behavioural  or 
compliance  reasons . Participants meeting exclusion criteria during the course of the study 
will be withdrawn.  
• The legal guardian and the paediatric participant have the right to withdraw permission 
(consent or assent, respectively) at any time during the study. If the study staff identify 
any reluctance in the legal guardian or paediatric participant (e.g. signs of verbal or 
physical dissent) about continued participation in the study, the paediatric participant’s 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 48  
 
 continuation in the study should be re-evaluated . The same pri nciples that govern 
permission/assent/consent also govern its withdrawal. A participant will be withdrawn 
from the study if consent or assent if applicable (a  paediatric participant’s dissent should 
be respected)  is withdrawn . 
• At the time of discontinuing from the study, all reasonable efforts should be made by [CONTACT_776009], as shown in the SoA. See SoA (Table  1) for data to be collected at the time 
of study discontinuation and any evaluations that need to be completed.  
• The reason for discontinuation will be recorded in the eCRF.  
• The participant will be permanently discontinued from the study intervention and the 
study at that time.  
• If the participant  withdraws consent  for disclos ure of future information, the s ponsor may 
retain and continue to use any data collected before such withdrawal of consent . 
• If the particip ant requests to permanently discontinue  the study intervention , they will be 
withdrawn from the study. In the case of ongoing AE /SAEs or pregnancy , they will be 
asked to be followed for safety  (see Section 8.3.3  for follow -up of AEs/SAEs and Section 
8.3.5  for follow -up of pregnancies) . 
• If the p articipant  withdraws consent for any further contact , the investigator will explain 
in the medical records as to whether the withdrawal is only from further receipt of study 
intervention or also from study procedures and/or post -study intervention follow -up. This 
information must be entered in the eCRF.   
7.[ADDRESS_1065817] to follow -up if he /she repeatedly fails to return /be present  
for scheduled in-clinic or remote  visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to return to the clinic or be present 
remotely for a required study visit:  
• The site must attempt to contact [CONTACT_47995] m issed visit as soon 
as possible . The site should  counsel the participant  on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant  wishes to and/or should 
continue in the study.  
• Before a  participant  is deemed lost to f ollow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (where possible, three  telephone calls 
and, if necessary , a certified letter to the participant ’s last known mailing address or local 
equivalent methods). These contact [CONTACT_13140] ’s 
medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 49  
 
 8 STU DY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarised in the SoA  (see Table  1). Protocol  
waiver s and exemptions are not allowed.  
• Immediate  safety concerns  should be discussed with the s ponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention . 
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• Procedures conducted as part of the participant’s parent EOS Visit will be utili sed for 
screening and Inclusion Visit assessments . All evaluations must be reviewed to confirm 
that potential  participants meet all eligibility criteria.  
Eligible participants will enter this study ideally directly after completing the EOS Visit of the 
parent study (Study PVO -1A-301 or PVO -1A-202/PVO -1A-204) and after having signed the 
ICF. Any study assessments already performed at the parent EOS Visit will serve as the 
Inclusion Visit  assessment for Study CLIN -[ZIP_CODE] -452; the data will be either tr ansferred from 
the parent  study  database or will be enter ed again in the Study  CLIN -[ZIP_CODE] -452 eCRF  by [CONTACT_112769]  (see details in Table  1). For assessments not performed in the parent study (i.e. 
spi[INVESTIGATOR_038])  or assessments performed out of allowed time window,  assessments will be 
performed  in-clinic or remotely  at the Study CLIN -[ADDRESS_1065818] , and in that order,  before any other 
assessments  are completed.  
8.1.1 FOP -PFQ  
Physical function will be assessed using the FOP -PFQ at the Inclu sion Visit, Follow -up Visits 
and the EOS/EW Visit.  
The FOP -PFQ is a disease -specific patient -reported outcome measure of physical impairment 
which includes questions related to ADL and physical performance. The adult form (developed 
for participants ≥15 ye ars old) will be used for all participants.  
The adult FOP -PFQ consists of 28 questions which are scored on a scale of 1 to 5, with lower 
scores indicating that the participant has more difficulty completing those tasks. A total score, 
upper extremities sub score and a mobility subscore is calculated. Score calculations are 
described in Section [IP_ADDRESS] . 
8.1.2 PROMIS Global Health Scale  
Physical and mental func tion will be assessed using the PROMIS Global Health Scale at the 
Inclusion Visit, at the Follow -up Visits and the EOS/EW Visit.  
The PROMIS Global Health Scale is a patient -reported outcome measure of physical and 
mental function. The adult form (developed  for participants ≥15 years old) will be used for all 
participants.  
The PROMIS Global Health Scale consists of 10 questions from which two scores are 
calculated: the global physical health score and the global mental health score, both ranging 
from 4 (wors e health) to 20 (better health). Scores are converted to T -scores, with a higher 
T-score value indicating better health. Score calculations and conversion to T -scores are 
described in Section [IP_ADDRESS] . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 50  
 
 8.1.3 CAJIS  
The CAJIS for FOP will be performed at the Inclusion Visit , Follow -up Visits and the EOS/EW 
Visit . 
The CAJIS is an objective measure of joint movement completed by [CONTACT_776010] ( Kaplan et al., 2017b ). This scale, which was developed by 
[CONTACT_776011], assesses 
functional disability by [CONTACT_776012] 1 2 joints (both right and left 
shoulder, elbow, wrist, hip, knee and ankle joints) and three body regions (cervical spi[INVESTIGATOR_050], 
thoracic/lumbar spi[INVESTIGATOR_566862]), with each joint/region assessed as: 0=normal (<10% deficit); 
1=partially impaired (10% to 90% deficit) ; 2=functionally ankylosed (>90% deficit). The 
CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 
(no involvement) to 30 (maximally involved).  
The examiner must also note and record (yes/no) if the participant:  
• Can walk;  
• Uses a wheelchair;  
• Needs some help with ADL ; 
• Needs complete help with ADL . 
8.1.4 FOP Assistive Devices Assessment  
The use of assistive devices and adaptations for daily living will be collected using the FOP 
assistive devices assessment at the Inclusion Visit, Follow -up Visits and the EOS/EW  Visit . 
Assistive devices and adaptations for daily living include:  
• Mobility aids (cane/crutch, walker, manual wheelchair, motorised scooter, customised 
motorised wheelchair, adapted vehicle for driving or fo r motorised wheelchair);  
• Eating tools (adapted eating utensils, customised height table for eating/customised chair 
for eating, customised table for eating attached to wheelchair, straws for drinking, 
blender for pureeing foods, adapted cooking utensils);  
• Personal care tools (hearing aids, reaching stick, dressing stick, compression socks, 
customised clothing, standard shoe lift for support, customised shoe soles, portable urinal 
for male and females, adapted comb/brush/bathing tools/toothbrush/shaver/cosme tic 
application tools, pi[INVESTIGATOR_775949], medical alert bracelet with annual emergency membership, 
‘In Case of Emergency’ Taggisar with annual membership and label for emergency care, 
customised dental care tools);  
• Bathroom aids and devices (barrier -free roll i n shower, shower seat/chair, handicap 
height toilet, washlet toilet, portable commode, lift seat on toilet, adapted sink 
counter/height/faucet handles/pi[INVESTIGATOR_151097], shower grab bars, shower handheld sprayer, tub 
lift, bathroom grab bars);  
• Bedroom aids and device s (memory foam bed mattress/pi[INVESTIGATOR_50151], bed with motorised lift 
system, airflow mattress, waterbed, bed safety rails, bed pull/strap for self -positioning, 
remote control devices for lights/window treatment/shades);  
• Home adaptions (floor level threshold on all  doorways, wide doorways to allow 
wheelchair access, transfer lift for bathing and mobility around the house, portable 
transfer lift, permanent built in ramp for home, portable ramp for use in 
home/office/travel, automatic light switches, customised furnit ure, customised counters 
in your kitchen/bathroom/work area, lift chair, durable/easy care flooring due to 
wheelchair weight, padded flooring for protection for children, handicapped emergency 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 51  
 
 exits, sliding/pocket interior doors, remote control/hands free  exterior door opener and 
closer, combination emergency fire/carbon monoxide detectors and alert)  
• Work environment adaptions (customised desk/office chair/workstation/office tools, use 
of handicapped bathroom facilities);  
• Technology adaptions (adapted keyb oard, voice activated computer software, wireless 
keyboard and mouse, trackball, adapted stand for computer use, typi[INVESTIGATOR_775950], onscreen 
keyboard that is not normally part of the device);  
• Sports and recreation adaptions (protective helmet/body gear, adapted  bicycle, other 
adapted recreational gear);  
• School adaptions (adapted desk, adapted chair, reaching tools, special electronics for 
learning, adapted curriculum);  
• Medical therapi[INVESTIGATOR_775951] (supplemental oxygen, physical therapy, hydrotherapy, 
energ y medicine therapy, occupational therapy, lymphoedema massage treatments and 
wraps, wound care specialist, positive expi[INVESTIGATOR_775952]).  
8.1.[ADDRESS_1065819] 6 months /since the last visit .  
8.1.6 Lung Function Assessments  
Lung function will be assessed at the Inclusion Visit , Follow -up Visits and at the EOS/EW 
Visit.  
The lung function parameters of observed FVC (litres) and % predicted FVC, observed FEV 1 
(litres) and % predicted FEV 1 and the absolute and predicted FEV 1/FVC ratio are obtained by 
[CONTACT_15209][INVESTIGATOR_038].  
The parameters of observed (traditional unit of mL/min/mmHg or International System of Units 
(SI unit) of mmol/min/kPa) ( Graham et al., 2017 ) and % predicted DLCO is obtained by [CONTACT_776013].  This provides information on the efficiency of gas transfer from alveolar air into 
the bloodstream. Carbon monoxide has a high affinity for haemoglobin, and it follows the same 
pathway as that of oxygen to finally bind with haemoglobin. Inhaled carbon mon oxide  is used 
for this test due to its high affinity for haemoglobin which is 200 -250 times that of oxygen 
(Modi and Cascella, 2020 ). 
8.1.7 Flare -up Assessment  
For each flare -up, the location of the flare -up, flare -up cause, flare -up start and stop date, 
whether it is ongoing, flare -up concomitant medication , symptoms  and outcome (resulted in 
extra bone growth, restricted movement) will be collected at the Inclusion Visit  (for ongoing 
flare-up, data from parent EOS Visit will be entere d again in the Study CLIN -[ZIP_CODE] -452 
eCRF) , the Follow -up Visits and the EOS/EW Visits.  
Symptoms of a flare -up typi[INVESTIGATOR_84688], but are not limited to, localised pain, soft tissue 
swelling/inflammation, redness, warmth, decreased joint range of motion  and stiffness. Only 
one symptom is required to define a flare -up. Flare -ups can occur in the absence of any apparent 
causative factor, but there is a high risk that substantial traumatic events (e.g. surgery, 
intramuscular immunisation, mandibular blocks for dental work, muscle fatigue, blunt muscle 
trauma from bumps, bruises, falls or influenza -like viral illnesses) can lead to a flare -up and 
result in heterotopic bone formation.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065820] visit, the location of the flare -ups, the start and stop date or whether it is ongoing, if 
any flare -up concomitant medication was taken and whether the flare -up resulted in extra bone 
growth and/or restricted movement. When  extra  bone growth  occurred , the location will be 
specified and the  investigators will ask the participant how the extra bone growth  affected their 
movement . 
Bone growth, loss of mobility and audiology impact that occurs as a consequence of a flare -up 
will be reported as an AE or SAE ( see Section  10.3.1 ). 
8.1.8 Extra Bone Growth Assessment  (without associated flare -up) 
For each extra bone growth (without associated flare -up) the location of the extra bone growth, 
whether it was preceded by [CONTACT_93356], illness, vaccination and/or other events (“yes”, “no” or 
“unknown”), extra bone growth start date , duration  and whether it is  ongoing, will be collected 
at the Inclusion Visit  and Follow -up/EO S/EW Visits.  
At each visit, the investigator will ask the participant if they experienced any extra bone growth 
(without associated flare -up) since their last visit and the details of these  extra bone growths.  
8.1.9 Qualitative Participant  Interviews  
In-depth qualitative interviews will be proposed to all participants  and will be conducted  in 
person or  by [CONTACT_776014]/ qualified site staff . Interviews can be carried out anytime 
within 1 year (ideally within 1  month) following  the Inclusion Visit  with consenting 
participants . 
Participants will be asked to describe her/his past experience with FOP (e.g. symptoms, joint 
being locked ) and with palovarotene (e.g. decrease in number of flare -ups, delay in physical 
disability,  overall satisfaction).  
Participants will also be asked  to describe : 
• the overall impact of the disease on them (e.g. physical  functioning , emotional health , 
social  functioning , work/school /daily  life impacts);  
• the critical join ts involved;  
• the emotional benefit of using palovarotene as a treatment for FOP ; 
• the perceptions of benefits and risks of palovarotene . 
The conduct of the qualitative interviews and all related procedures will be described in the 
interview guide.  For the c ollection and reporting processes of the AEs/SAEs during the 
qualitative interviews, please refer to Section 8.3. 
8.2 Safety Assessments  
The assessment of AEs/SAEs is detailed in Section 8.3. 
8.2.1 Spi[INVESTIGATOR_775953] ’ spi[INVESTIGATOR_775954]  ‘radiological vertebral fracture ’.  
The spi[INVESTIGATOR_775955] (e.g., CT, x -ray, scint igraphy , etc)  
at the Inclusion Visit, at the Follow -Up Visit annually and at the EOS/EW Visit.  This 
assessment may be performed locally.  
The data from the spi[INVESTIGATOR_775956]  (less than 3 months 
before entry  in CLIN -[ZIP_CODE] -452 study)  should be entered  in the CLIN -[ZIP_CODE] -452 eCRF by [CONTACT_776015] . If the spi[INVESTIGATOR_775957] 3 
months before  entry in CLIN -[ZIP_CODE] -452 study , a new spi[INVESTIGATOR_775958].  Spi[INVESTIGATOR_775959].  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 53  
 
 The radiolo gical imaging can be done locally and the  spi[INVESTIGATOR_775960] . If any vertebral fracture s are identified, 
these should be reported as AE s and the corresponding eCRF page should be completed . 
8.2.2 C-SSRS and Suicidal Ideation and Behaviour Risk Monitoring  
Suicidal ideation and behaviour will be collected using the C -SSRS  (‘Baseline ’ version)  at the 
Inclusion Visit  for screening purposes.  At Follow-up visits, the C-SSRS ‘Since Last Visit’ 
version will be used.  
The adult form (designed for participants ≥12  years of age) will be used for all participants. 
Any participant reporting type [ADDRESS_1065821] been reported in patients treated with systemic retinoids. In addition, there is 
a relatively high background prevalence (24%) of depression in untreated patients with FOP.  
Therefore, participants being treated with palovarotene  should be monitored appropriately and 
observed closely for suicidal ideation and behaviour or any other unusual changes in behaviour, 
especially at the beginning and end of the course of intervention, or at the time of dose changes, 
either increases or decreases. Participants who experience signs of suicidal ideation or 
behaviour should undergo a risk assessment. All factors contributing to suicidal ideation and 
behaviour should be evaluated and consideration should be given to discontinuation of the study 
intervention.  
When informed consent or assent has been given, families and caregivers of participants being 
treated with palovarotene  should be alerted about the need to monitor participants for the 
emergence of unusual chan ges in behaviour, as well as the emergence of suicidal ideation and 
behaviour and to report such symptoms immediately to the study investigator. Suicidal ideation 
and behaviour will be captured as an AE/SAE.  
8.2.[ADDRESS_1065822], ALT and triglyceride levels from the EOS of parent studies and centrally 
measured will be used at the Inclusion Visit for screening purposes.  
For participants being screened more than one month after EOS visit of parent study, b lood 
samples will be co llected under fa sting conditions  when possible and testing preformed at a 
local, qualified laboratory.  
The participant will not be eligible to participate in the study if:  
• Any of the exclusion criteria apply (Section 5.2); 
• Amylase or lipase is >2× above the ULN;  
• AST or ALT is >2.5× above the ULN;  
• Fasting triglycerides levels are >400 mg/dL with or without therapy.  
8.2.4 Line ar Height and Body  Weight  
Linear height and body  weight will be collected for all participants at the Inclusion Visit , the 
Follow -up Visits and the EOS/EW Visit.  
Height at 6 to 12 months prior to the Inclusion Visit will also be collected.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 54  
 
 8.2.5 Vital Signs  
Respi[INVESTIGATOR_697], blood pressu re and heart rate will be collected at the Inclusion Visit , the 
Follow -up Visits and the EOS/EW Visit.  
• Blood pressure and pulse measurements will be assessed by [CONTACT_776016] . An 
automated device should not be used due to the risk of over -inflation and  potential tissue 
injury in participants  with FOP . To minimise the potential for a flare -up at the cuff site 
when measuring blood pressure, the cuff should be pumped slowly to a maximum of 
140 mm Hg. Blood pressure should not be measured on an arm with a f lare-up. 
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_1065823] 
for the participant in a quiet setting without distractions (e.g. television, cell phones).  
• Vital signs will be measured after [ADDRESS_1065824] and will include respi[INVESTIGATOR_697],  systolic 
and diastolic blood pressure and pulse . 
8.2.6 Pregnancy Testing  
Female participants are assessed for child -bearing status and pregnancy prevention measures 
prior to receiving palovarotene . Refer to Section 5.1 for pregnancy testing entry criteria . 
Pregnancy tests may be performed  either with  the assistance from a study nurse  at home or self -
administered by [CONTACT_2299] .  
 
According to local practice, medically documented blood or urine pregnancy tests should be 
performed, as follows  (the results of which will be recorded in the eCRF) : 
• Prior to starting therapy:  at least one month after the participant has started using 
contraception, and shor tly (preferably a few days) prior to the first prescription, the 
participant should undergo a pregnancy test. This test should ensure the participant is not 
pregnant when she starts treatment with palovarotene and should be documented within 
the patient me dical records.  
• Follow -up pregnancy testing during treatment:  follow -up pregnancy tests should be 
done monthly. The need for repeated medically documented pregnancy tests every month 
is required and should be determined according to local practice including  consideration 
of the participant's sexual activity and extent of FOP disease burden.  
• End of treatment:  one month after stoppi[INVESTIGATOR_056], women should undergo a final 
pregnancy test.  
Palovarotene is strictly contraindicated during pregnancy , therefore if the pregnancy test is 
positive at the Inclusion Visit , the participant will not be eligible to participate in the study. Any 
positive pregnancy test during the study will result in immediate discontinuation of 
palovarotene. If a participant becomes pregnant during the study, she will be followed 
throughout her pregnancy and the health status of the baby [CONTACT_776017] (see Section 8.3.5 ). 
8.3 AEs and S AEs and Other Safety Reporting  
The definitions of AEs and SAEs can be found in Section  10.3. 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legal guardian ). 
The investigator and any qualified designees are responsible f or detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs or their sequelae (any AE, based on the investigator’s opi[INVESTIGATOR_1649], not only those assessed 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 55  
 
 as related ) that persist after the date of palovarotene discontinuation, or that caused the 
participant to discontinue palovarotene  (see Section 7). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section  10.3. 
8.3.1 Time Period and Frequency for Collecting AE and SAE Information  
All AEs (including SAEs) will be collected from the signing of the ICF until  last study 
intervention intake +  30 days at the time points specified in the SoA ( Table  1). 
All AEs that first occurred during participation in the pare nt study and are ongoing at the time 
of transition to Study CLIN -[ZIP_CODE] -452 will be collected and entered again as ongoing 
AEs/SAEs in the Study CLIN -[ZIP_CODE] -452 eCRF at the signing of the ICF.  
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance should this exceed 24 hours  of awareness of the event , as indicated in Section  10.3. 
The investigator  will submit any updated SAE data to the sponsor within 24  hours of it being 
available.  
Investigators are not obligated to actively seek information on AEs  or SAE s after conclusion of 
the study participation  (unless any AEs /SAEs  or their sequelae persist after this date, follow -up 
is required until the event or its sequelae resolve or stabilise , or the participant is lost to follow -
up). However, if the investigator learns of any SAE, at any time after a participant has been 
disch arged from the study, and he/she considers the event to be reasonably related to the study 
intervention or study participation, the investigator must promptly notify the sponsor  (through 
pharmacovigilance) . 
8.3.2 Method of Detecting AEs and SAEs  
Care will be tak en not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.3.3 Follow -Up of AEs and SAEs  
After the initial AE/SAE report, the investigator is  required to proactively follow each 
participant at subsequent visits/contacts. Follow‑up of the AE/SAE after the date of 
palovarotene discontinuation is required until the event or its sequelae resolve or stabilise at a 
level acceptable to the investigato r and the sponsor’s clinical monitor or his/her designated 
representative, or the participant is lost to follow -up (as defined in Sectio n 7.3). Further 
information on follow -up procedures is provided  in Section  10.3. 
8.3.4 Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_776018] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety 
of a study intervention under clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, institutional review board 
(IRB)/independent ethics committee ( IEC), and investigators.  
• An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (e.g. summary or listing of SAEs) from the sponsor will 
review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 56  
 
 • Investigator safety reports must be prepared by [CONTACT_776019] (S[LOCATION_003]R) according to local regulatory requirements and 
sponsor ’s policy and forwarded to investigators as necess ary. 
8.3.5 Pregnancy  
• Details of all pregnancies in female participants will be collected from the signing of the 
ICF and until one year  after the end of treatment  within Study CLIN -[ZIP_CODE] -452. 
• Any female participant who becomes pregnant while participating in the study will 
discontinue the study intervention and be withdrawn from the study.  
• If a pregnancy is reported, the investigator will record pregnancy information on the 
appropriate form s (AE form, in the eCRF and 080479 -FOR Drug Exposure for 
Pregnancy Form – paper form) and submit it to  the sponsor within  24 hours  of learning 
of the female participant ’s pregnancy  (detailed in Section  10.2). 
• Any pregnancy complication or elective termination of a pregnancy for medical reasons 
will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes (e .g. spontaneous abortion, foetal  death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported as 
such. 
• The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participan t and follow -up 
information on the neonate up until one year of age and the information will be forwarded 
to the sponsor  using the appropriate forms . 
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_776020]  8.3.4 . While the investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
• For female participant s who have not reached legal age and  who become pregnant, this 
information will be shared with the participant’s legal guardian if and as  required by [CONTACT_13125] . 
8.3.6 Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs  
Not applicable.  
8.3.[ADDRESS_1065825] been formally defined during palovarotene clinical 
development.  
8.3.8 Reporting of Study Intervention Errors Including Misuse/ Abuse  
• Medication errors are unintentional errors in the prescribing, dispensing, administration 
or monitoring of a study intervention  (medicinal product) while under the control of a 
healthcare professional, participant  or consumer ( EMA  definition).  
• Misuse refers to situations where the study intervention  is intentionally and 
inappropriately used not in accordance with the protocol.  
• Abuse corresponds to the persistent or sporadic, intentio nal excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584].  
• Study intervention errors and uses outside of what is foreseen in the protocol will be 
recorded in the eCRF in the AE section.  It will be  reported in the safety database  only if 
associated with an SAE.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 57  
 
 • Misuse or abuse will be collected and reported (via SAE form) in the safety database , 
whether  associated or not with an AE/SAE , within 24 hours of investigator’s or qualified 
designees’ awareness.  
8.4 Pharmacokinetics  
Pharmacokinetic  parameters are not evaluated in this study . 
8.5 Genetics  
Genetics are not evaluated in this study.  
8.6 Biomarkers  
Biomarkers are not evaluated in this study.  
8.7 Immunogenicity Assessments  
Immunogenicity is not evaluated in this study.  
8.8 Medical Resource Utili sation and Health Economic s 
Medical resource utili sation and health economics  parameters are not evaluated in this study . 
8.9 Demographic and Baseline Characteristics  
The following data will not be collected or recorded in the Study CLIN -[ZIP_CODE] -452 eCRF ; these 
data will be transferred  from the  final parent stud y database and summarise d: 
• Disease h istory including the date of symptom onset, date of diagnosis by a physician, 
method of diagnosis, date of genetic test if performed and type of FOP genetic mutation.  
• Flare -up history over the past 12 months prior to the Inclusion Visit  including : location 
of flare -ups, cause, flare -up start and stop date, flare -up concomitant medication and 
outcome (resulted in extra bone growth, restricted moveme nt). Symptoms of a flare -up 
typi[INVESTIGATOR_84688], but are not limited to, localised pain, soft tissue swelling/inflammation, 
redness, warmth, decreased joint range of motion  and stiffness.  
The following will be collected at the Inclusion Visit : 
• Baseline demog raphics including age, gender and race.  
• Physical examination including a general assessment, skin, lymph nodes, head, eyes, 
ears, nose and throat (HEENT), thorax , lung, cardiovascular system , abdomen, 
extremities, musculoskeletal  system , neurologic al system  and other . 
Any post -Inclusion Visit abnormal findings considered clinically significant by [CONTACT_776021] a n AE/SAE.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065826] draft of the statistical analysis plan (SAP) will be made available within the first three 
months following the  first participant first visit and will include a more technical and detailed 
description of the statistical analyses described in this section. This section is a summary of the 
planned statistical analyses of the  primary and secondary endpoints . 
9.[ADDRESS_1065827] been performed as the sample size is dependent on the 
number of participants in the parent studies who are eligible. A maximum of 87 participants 
from studies PVO -1A-301, PVO -1A-202/PVO -1A-204 are eligible to be  enrolled.  
9.3 Analys is Sets 
For the purposes of analysis, the following analysis set s are defined:  
Participant Analysis Set  Description  
Screened Set  All participants who signed the ICF  
Enrolled Set  The Enrolled Set will contain all participants who were assigned to receive 
palovarotene in Study CLIN -[ZIP_CODE] -452. 
Full Analysis Set 
(FAS)/ Safety  Set The FAS/S afety Set will contain all participants who receive d at least one 
dose of palovarotene  during Study CLIN -[ZIP_CODE] -452.  
Per Protocol (PP)  Set The PP set wi ll contain all participants from the FAS who did not experience 
any major protocol deviations that may interfere with safety/efficacy 
evaluations  
9.4 Statistical Analyses  
9.4.1 General Considerations  
Statistical evaluation will be performed using Statistical Analysis System (SAS®) (Version  9.4 
or higher).  
No formal statistical testing will be performed . All the analyses will be primarily descriptive in 
nature. If p-values are presented, they will be for exploratory purposes only.  
For descriptive analyses, summary statistics will be presented at each scheduled visit and will 
include sample size, number of available observations (N), number of missing observations 
(missing), mean, 95% CIs of the mean/median, standard deviation (SD), number of nonmissing 
obser vations (n), median and range for continuous variables and scores. For categorical or 
discrete variables, the absolute and relative (percentage) numbers based on the nonmissing 
number of observations for each category will be presented, including 95% CIs.  
Missing data will not be replaced but will be displayed in all relevant tables.  
The Inclusion Visit  is the first study visit  (Day 1)  and first administration of palovarotene in 
Study CLIN -[ZIP_CODE] -452 (and corresponds to the EOS Visit of the parent study for assessments 
already performed in the parent study ). 
All analyses will be performed by [CONTACT_111584] ( PVO -1A-301 or PVO -1A-202/PVO -1A-204), 
by [CONTACT_776022] -[ZIP_CODE] -452 (treated, not treated) 
and treatment regimen (chronic treatment only, flare -up treatment only, chronic & flare-up 
treatment ) and overall.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065828] occurred during participation in the parent s tudy and is ongoing at the time 
of transition to Study CLIN -[ZIP_CODE] -452 will therefore be a  (non-TEAE)  AE. 
All ongoing AEs from the parent study and all TE AEs that occur following the signing of the 
ICF until last study intervention intake +  30 days will be included in the participant data listings 
using the Full Analysis Set ( FAS)/Safety  Set. Primary endpoint a nalyses and summary tables 
will be presented by [CONTACT_111584] , by [CONTACT_776022] -
[ZIP_CODE] -452 and tre atment regimen and overall for the FAS/ Safety  Set. 
Adverse events /TEAEs  will be coded according to Medical Dictionary for Regulatory 
Activities (MedDRA) and will be classified by [CONTACT_6215]. Adverse events /TEAE  listings 
will be presented by [CONTACT_3445], SO C and PT.  
The incidence of all reported TEAEs , serious and nonserious treatment -related TEAEs , all 
serious TEAEs , all nonserious TEAEs , TEAEs leading to death  and TEAEs leading to treatment 
discontinuation will be tabulated separately. In addition, summary  tables for TEAEs  will be 
presented by [CONTACT_776023] ( investigator -reported 
causality assessment).  
9.4.3 Analys is of Secondary Endpoint s 
Data related to the secondary endpoints will be included in the participant data listings using 
the FAS/Safety  Set. Secondary endpoint a nalyses and summary tables will be presented by 
[CONTACT_111584] , by [CONTACT_776022] -[ZIP_CODE] -452 and 
treatment regimen and overall for the FAS/Safety  Set. 
Analyses of the secondary endpoints will be repeated on the Per Protocol ( PP) Set if ≥10% of 
participants are excluded from the FAS/Safety Set.  
Data will be tabulated descriptively, i.e. the number and percentage of participants for each 
category for categorical parameters, and the number, mean, SD, 95% CIs of the mean/median, 
median, minimum and maximum for continuous parameters will be tabulated . 
[IP_ADDRESS]  FOP -PFQ  
The adult FOP -PFQ consists of 28 questions which are scored on a scale of 1 to 5. A total score, 
upper extremities subscore and a mobility subscore is calculated as follows : 
• Total score : the sum of the scores from each question which will range f rom 28 × 1 = 28 
to 28 × 5 = 140.  
• Upper extremities subscore: the sum of the scores from 15 questions (Questions 1 -12, 
14, 25 and 26) which will range from 15 × 1 = 15 to 15 × 5 = 75.  
• Mobility subscore: the sum of the scores from 13 questions (Questions 13,  15-24, 27 and 
28) which will range from 13 × 1 = 13 to 13 × 5 = 65.  
Missing scores for individual questions will not be imputed, but they will be taken into account 
according to the rules described below:  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 60  
 
 (1) If more than 20% of the questions contributing to the total score are missing, the total 
score will not be calculated. It will be considered as missing.  
(2) If less than 20% of the questions contributing to the total score are missing, the total score 
will be calculated by [CONTACT_776024] , divided by [CONTACT_776025] (i.e. × 28).  
The two rules described above also apply to the upper extremities subscore and the mo bility 
subscore.  
The scores will be transformed to reflect a percentage of worst score. The percentage of worst 
score ranges from 0% to 100% with 0% indicating the best possible function and 100% 
indicating the worst possible function.  
The % of worst score s (for total score, upper extremities subscore and mobility subscore) as 
well as the change from the Inclusion Visit  will be presented for each visit.  
[IP_ADDRESS]  PROMIS Global Health Scale  
The PROMIS Global Health Scale consists of 10 questions from which the global physical 
health score and the global mental health score, both ranging from 4 (worse health) to 20 (better 
health), is calculated as follows:  
• Global physical health score : the sum of scores from Questions 3, 6, 7 and 8 and will 
range from 4 (worse health) to 20 (better health).  
• Global mental health score : the sum of scores from Questions 2, 4, 5 and 10 and will 
range from 4 (worse health) to 20 (better health).  
In the calculation of the above scores, the Question 7, 8 and 10 will be rescaled as shown in 
Table  6. 
If a participant is missing any of the contributing raw scores, the corresponding score (global 
physical health or global mental health score) will  not be calculated for that participant.  
Table  6 Rescaled Global Physical and Mental Health Scores for the Adult Version of the PROMIS  
Global Health Scale  
Questions  Raw Score  Rescaled Score  
7 0 5 
1-3 4 
4-6 3 
7-9 2 
10 1 
8 and 10  1 5 
2 4 
3 3 
4 2 
5 1 
PROMIS=Patient Reported Outcomes Measurement Information System . 
The global physical health score  and the global mental health score will be converted into 
T-scores  (see Table  7). T-score distributions are standardised such that a value of 50 represents 
the average (mean) for the general population and increments of ±10 points represent ±[ADDRESS_1065829] from the norm. Higher T -scores indicate better physical/mental health. A T -score <50 
indicates worse health than the general population, while a T -score >50 indicates better health.  
For example, a participant who has a T -score o f 60 is 1 SD better (healthier) than the general 
population.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: [ADDRESS_1065830] Error  
4 16.2 4.8 4 21.2 4.6 
5 19.9 4.7 5 25.1 4.1 
6 23.5 4.5 6 28.4 3.9 
7 26.7 4.3 7 31.3 3.7 
8 29.6 4.2 8 33.8 3.7 
9 32.4 4.2 9 36.3 3.7 
10 34.9 4.1 10 38.8 3.6 
11 37.4 4.1 11 41.1 3.6 
12 39.8 4.1 12 43.5 3.6 
13 42.3 4.2 13 45.8 3.6 
14 44.9 4.3 14 48.3 3.7 
15 47.7 4.4 15 50.8 3.7 
16 50.8 4.6 16 53.3 3.7 
17 54.1 4.7 17 56 3.8 
18 57.7 4.9 18 59 3.9 
19 61.9 5.2 19 62.5 4.2 
20 67.7 5.9 20 67.6 5.3 
PROMIS=Patient  Reported Outcomes Measurement Information System . 
Actual values as well as the change from the Inclusion Visit  in mean global physical and mental 
health score converted into T -scores will be presented for each visit.  
[IP_ADDRESS]  CAJIS  
Actual values as well as the change from the Inclusion Visit in CAJIS total score will be 
presented for each visit.  
[IP_ADDRESS]  FOP Assistive Devices  
Actual values as well as the shift from the Inclusion Visit in the use of assistive devices and 
adaptions for daily living will be presented for each visit.  
[IP_ADDRESS]  Healthcare Utilization  
Descriptive statistics will be presented for each visit.  
[IP_ADDRESS]  Lung Function Parameters  
Actual values as well as the change from the Inclusion Visit in observed and % predicted FVC, 
observed and % predicted FEV 1, absolute and predicted FEV 1/FVC ratio and observed and % 
predicted DLCO will be presented for each visit.  
The DLCO value is reported in either traditional units (mL/min/mmHg) or SI units 
(mmol/min/kPa). Values in SI units can be multiplied by 2.987 to obta in values in traditional 
units ( Graham et al., 2017 ). 
[IP_ADDRESS]  Flare -ups 
Actual values as well as the change from the Inclusion Visit  in number of investigator -reported 
flare-ups, flare -up outcomes ( extra bone growth, restricted movement) and flare -up duration 
will be presented for each visit by [CONTACT_776026].  
[IP_ADDRESS]  Extra Bone Growth  
The percentage of participants with extra bone growth  (associated with a flare -up and not 
associated with a flare -up) will be presented for eac h visit.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 62  
 
 [IP_ADDRESS]  Qualit ative Participant  Interviews  
No formal hypotheses will be tested given the qualitative nature of the analyses.  
The s ervice Provider (SP) will begin the analysis process based on the PI/ qualified site staff 
debrief and record  of initial thoug hts from each of the completed interviews. Specifically, using 
field notes  (where available) , the PI/qualified site staff  will identify key concepts raised by 
[CONTACT_776027] a particular focus on the study 
objective s and other potential insights emerging from the interviews. Additionally, once the 
interview transcripts are available, the SP will analyse the interview data according to the final 
qualitative analysis plan , using a thematic qualitative data analysis app roach.  
All qualitative and limited quantitative data will be summarised descriptively. Where 
applicable, Ns and % s will be provided.  
Tables displaying the concepts described during the interviews will be developed to document 
the results of the interviews.  Additionally, descriptive statistics based on the quantitative data 
obtained during the interviews (e.g. symptom improvements during the clinical study) will be 
computed and summarised.  
9.4.4 Other Analyses  
[IP_ADDRESS]  Demographic and Baseline Characteristics  
Disease and flare -up history will be summarised using the data transferred  from  the final parent 
study database . 
Baseline demographic and p hysical examination  data will be included in the participant data 
listings and descriptive statistics presented using the FAS/Safety  Set. 
Physical examination findings  will be coded using MedDRA and summarised.  
[IP_ADDRESS]  Prior and Concomitant Medication  
Prior medication will be summarised at the Inclusion Visit  using the data transferred  from  the 
final parent stud y database . 
Concom itant medication will be included in the participant data listings using the FAS/ Safety 
Set. 
Descriptive statistics of concomitant medication will be presented for the FAS/ Safety Set.  
Concomitant medication will be coded using the World Health Organization  Drug Dictionary 
(WHODD) and summarised by [CONTACT_776028].  
[IP_ADDRESS]  Concomitant Procedures  
Concomitant procedure data will be included in the participant data listings using the 
FAS/ Safety Set.  
Descriptive statistics of concomitant procedure s will be presented for the FAS/ Safety Set.  
[IP_ADDRESS]  Spi[INVESTIGATOR_775961]/Safety Set.  
Descriptive statistics of spi[INVESTIGATOR_775962]/Sa fety Set.  
[IP_ADDRESS]  Linear Height and Body Weight  
Linear height and body weight will be included in the participant data listings using the 
FAS/ Safety Set.  
Actual values and mean changes from the Inclusion Visit  in linear  height and body weight will 
be presented at  each visit for the FAS/ Safety  Set. 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  PAGE 63  
 
 Height velocity and z -scores will be derived for participants <18  years of age. Actual values 
and mean changes from the Inclusion Visit in height velocity and z -scores will be presented at 
each visit for the FAS/Safety S et. 
[IP_ADDRESS]  Vital Signs  
Vital signs (respi[INVESTIGATOR_697], blood pressure and heart rate) will be included in the participant 
data listings using the FAS/ Safety  Set.  
Actual values and mean changes from the Inclusion Visit  in respi[INVESTIGATOR_697], blood pressure and 
heart  rate will be presented at each visit for the FAS/ Safety  Set. 
[IP_ADDRESS]  Participant Disposition and Withdrawals  
The numbers and percentages of participants included in the analysis sets will be tabulated 
overall , by [CONTACT_776029]. The reasons for participant exclusions from 
each of the analysis sets will also be tabulated.  
In addition, the number of participants who discontinued treatment or withdrew from the study 
will be presented with the primary reasons for discontinuation/withdrawal.  
9.4.5 Subgr oups Analyses  
Subgroup analyses will be performed by  [CONTACT_111584]  (PVO -1A-301 or PVO -1A-202/PVO -1A-
204), palovarotene status at the time of transition to study CLIN -[ZIP_CODE] -452 (treated, not 
treated), and treatment regimen (chronic treatment only, flare -up treatment only, chronic & 
flare-up treatment ). 
Further details on the statistical analysis will be provided in the SAP.  
9.[ADDRESS_1065831] been completed  at the Inclusion Visit . 

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023   
 
 11 REFERENCES  
Baujat G, Choquet R, Bouée Set et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) 
in [LOCATION_009]: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis 
2017;12:123.  
Di Rocco M, Baujat G, Bertamino M et al. International physician survey on management of 
FOP: a modified Delphi study. Orphanet J Rare Dis 2017;12:110.  
Glaser DL, Rocke DM, Kaplan FS. Catastrophic falls in patients who have fibrodysplasia 
ossificans progressiva. Clin Orthop 1998;(346):110 -116. 
Graham BL, Brusasco V, Burgos F et al. 2017 ERS/AT S standards for single -breath carbon 
monoxide uptake in the lung. Eur Respir J 2017;49(1):1600016.  
Hoffman LM, Garcha K, Karamboulas K et al. BMP action in skeletogenesis involves 
attenuation of retinoid signaling. J Cell Biol 2006;174:101 –13. 
Hüning I, Gi llessen -Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic 
mutations and genotype -phenotype correlation. Mol Syndromol 2014;5:201 –11. 
The International Clinical Council on FOP (ICC). The Medical Management of Fibrodysplasia 
Ossific ans Progressiva: Current Treatment Considerations. January 2022.  
Kaplan FS et al. In: J Bilezikian et al., editors. Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism. 9th ed. Washington, DC: American Society for Bone and 
Mineral Res earch 2019a:865 –70. 
Kaplan FS, Al Mukaddam M, Baujat G et al. The International Clinical Council on FOP (ICC) 
and Consultants. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current 
Treatment Considerations. Proc Intl Clin Council FOP 201 9b;1:1 –111. 
Kaplan FS, Pi[INVESTIGATOR_566876], Al Mukaddam MM et al. Hard targets for a second skeleton: therapeutic 
horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opin Orphan Drugs 
2017a;5:291 –4. 
Kaplan FS, Al Mukaddam M, Pi[INVESTIGATOR_566876]. A cumulative an alogue joint involvement scale 
(CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone 2017b;101;123 -128. 
Kaplan FS, Zasloff MA, Kitterman JA et al. Early mortality and cardiorespi[INVESTIGATOR_775963].  J Bone Joint Surg Am 2010;92:686 –91. 
Kaplan FS, Lounev VY, Wang H et al. Fibrodysplasia ossificans progressiva: a blueprint for 
metamorphosis. Ann N Y Acad Sci 2011;1237:5 –10. 
Kaplan FS, Xu M, Seemann P et al. Classic and atypi[INVESTIGATOR_775964] s progressiva 
(FOP) phenotypes are caused by [CONTACT_776030] (BMP) type I 
receptor ACVR1. Hum Mutat 2009;30:379 –90. 
Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract 
Res Clin Rheumatol 2008;22(1).  
Koyama E, Golden EB, Kirsch T et al. Retinoid signaling is required for chondrocyte 
maturation and endochondral bone formation during limb skeletogenesis. Dev Biol 
1999;208:375 –91. 
Mattera MS, Kaplan FS, Pi[INVESTIGATOR_775965]. Patient -reported physi cal function outcome measure 
for adults with Fibrodysplasia Ossificans Progressiva: intelligent test design based on Promis 
item banks. Value Health 2015;8:A165.  
Meyers C, Lisiecki J, Miller S et al. Heterotopic Ossification: A Comprehensive Review. JBMR 
Plus 2019;3:e10172.  

IPSEN GROUP  CLIN -[ZIP_CODE] -452 
CONFIDENTIAL  
PROTOCOL (INCL . AMENDMENT #3): FINA L VERSION 4. 0: 13 NOVEMBER 2023  
 
 Modi P, Cascella M. Diffusing Capacity of  The Lungs for Carbon Monoxide. [Updated 2020 
Apr 15]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK556149/  (Accessed Ma rch 2021).  
Peng K, Cheung K, Lee A et al. Longitudinal Evaluation of Pain, Flare -Up, and Emotional 
Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry. 
JBMR Plus 2019;3:e10181.  
Ortiz -Agapi[CONTACT_1639] F, Colmenares -Bonilla D. Quality of life of patients with fibrodysplasia 
ossificans progressiva. J Child Orthop 2015;9: 489 –93. 
Pi[INVESTIGATOR_566876], Cheung K, Kile S et al. Self-reported baseline phenotypes from the International 
Fibrodysplasia Ossificans Progressiva (FOP) Association Glob al Registry. Bone 
2020a;134:115274.  
Pi[INVESTIGATOR_566876], Kimel M, Whalen J, et al. Validity and reliability of the fibrodysplasia ossificans 
progressiva physical function questionnaire (FOP -PFQ), a patient -reported, disease -specific 
measure [Poster presentation]. A SBMR Annual Meeting Virtual Event, 2020b, 
11-15 September.  
Pi[INVESTIGATOR_566876], Cheung K, Kile S, et al. Self-reported baseline phenotypes from the International 
Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone 
2020 c;134:115274.  
Pi[INVESTIGATOR_566876], Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans 
progressiva: cross -sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis 
2019;14(1):[ADDRESS_1065832] -Gay C, Liljesthröm M et al. The Natural Histo ry of Flare -Ups in 
Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. J Bone 
Miner Res 2016;31:650 –6. 
Pi[INVESTIGATOR_566876], Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, 
management, and therapeutic horizons. Pedi atr Endocrinol Rev 2013;[ADDRESS_1065833] 2:437 –48. 
Qi Z, Luan J, Zhou X et al. Fibrodysplasia ossificans progressiva: Basic understanding and 
experimental models. Intractable Rare Dis Res 2017;6:242 –8. 
Sanchez -Duffhues G, de Gorter DJ, Ten Dijke P. Towards a cure for Fibrodysplasia ossificans 
progressiva. Ann Transl Med 2016;[ADDRESS_1065834] 1:S28.  
Shen Q, Little SC, Xu M et al. The fibrodysplasia ossificans progressiva R206H ACVR1 
mutation activates BMP -independent chondrogenesis and zebrafish embryo ventralization. J 
Clin Invest 2009;119:3462 –72. 
Shimono K, Tung WE, Macolino C et al. Potent inhibition of heterotopic ossification by [CONTACT_776031] -γ agonists [published correction appears in Nat Med. [ADDRESS_1065835];18(10):1592] Nat Med 2011;17:454 –60. 
Weston AD, Ch andraratna RA, Torchia J et al. Requirement for RAR -mediated gene repression 
in skeletal progenitor differentiation. J Cell Biol 2002;158:39 –51. 
Williams JA, Kondo N, Okabe T et al. Retinoic acid receptors are required for skeletal growth, 
matrix homeostas is and growth plate function in postnatal mouse. Dev Biol 2009;328:315 –27. 
Zhang W, Zhang K, Song L et al. The phenotype and genotype of fibrodysplasia ossificans 
progressiva in China: a report of 72 cases. Bone 2013;57:386 –91. 
